HUTCHMED (HCM) 6-K 28 Jul 21 2021 Q2 HUTCHMED Reports 2021 Interim Results and Provides Business Updates Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2021
Document and Entity Information
Document Type	6-K
Document Period End Date	Jun. 30, 2021
Entity Registrant Name	HUTCHMED (CHINA) LIMITED
Entity Central Index Key	0001648257
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 587,441,000	$ 235,630,000
Short-term investments	363,007,000	199,546,000
Accounts receivable-third parties	57,953,000	46,648,000
Accounts receivable-related parties	925,000	1,222,000
Other receivables, prepayments and deposits	32,118,000	26,786,000
Amounts due from related parties	24,225,000	1,142,000
Inventories	25,505,000	19,766,000
Total current assets	1,091,174,000	530,740,000
Property, plant and equipment	29,168,000	24,170,000
Right-of-use assets	9,523,000	8,016,000
Investments in equity investees	118,316,000	139,505,000
Other non-current assets	24,708,000	21,687,000
Total assets	1,272,889,000	724,118,000
Current liabilities
Accounts payable	28,513,000	31,612,000
Other payables, accruals and advance receipts	181,610,000	120,882,000
Bank borrowings	26,883,000
Lease liabilities	3,852,000	2,785,000
Other current liabilities	6,857,000	3,118,000
Total current liabilities	247,715,000	158,397,000
Lease liabilities	5,957,000	6,064,000
Bank borrowings		26,861,000
Other non-current liabilities	5,522,000	13,847,000
Total liabilities	259,194,000	205,169,000
Commitments and contingencies
Company's shareholders' equity
Ordinary shares; $0.10 par value; 1,500,000,000 shares authorized; 848,515,660 and 727,722,215 shares issued at June 30, 2021 and December 31, 2020 respectively	84,851,000	72,772,000
Additional paid-in capital	1,412,607,000	822,458,000
Accumulated losses	(517,996,000)	(415,591,000)
Accumulated other comprehensive income	5,333,000	4,477,000
Total Company's shareholders' equity	984,795,000	484,116,000
Non-controlling interests	28,900,000	34,833,000
Total shareholders' equity	1,013,695,000	518,949,000
Total liabilities and shareholders' equity	$ 1,272,889,000	$ 724,118,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Ordinary shares, par value (in US$ per share)	$ 0.10	$ 0.10
Ordinary shares, authorized (in shares)	1,500,000,000	1,500,000,000
Ordinary shares, issued (in shares)	848,515,660	727,722,215

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues
Total revenues	$ 157,362	$ 106,765
Operating expenses
Research and development expenses	(123,050)	(73,974)
Selling expenses	(18,007)	(5,673)
Administrative expenses	(36,790)	(21,711)
Total operating expenses	(301,096)	(184,930)
Loss from operations	(143,734)	(78,165)
Other income, net of other expenses	3,287	1,585
Loss before income taxes and equity in earnings of equity investees	(140,447)	(76,580)
Income tax expense	(1,859)	(2,032)
Equity in earnings of equity investees, net of tax	42,966	30,366
Net income	(99,340)	(48,246)
Less: Net income attributable to non-controlling interests	(3,057)	(1,448)
Net income attributable to the shareholders of equity investee	$ (102,397)	$ (49,694)
Losses per share attributable to the Company-basic and diluted (US$ per share)	$ (0.14)	$ (0.07)
Number of shares used in per share calculation-basic and diluted	729,239,181	685,285,841
Third parties
Revenues
Total revenues	$ 154,790	$ 104,441
Related parties
Revenues
Total revenues	2,572	2,324
Goods | Third parties
Revenues
Total revenues	129,148	94,889
Operating expenses
Costs of goods and services	(107,511)	(82,186)
Goods | Related parties
Revenues
Total revenues	2,311	2,084
Operating expenses
Costs of goods and services	(1,673)	(1,386)
Commercialization services
Revenues
Total revenues	15,030
Commercialization services | Third parties
Revenues
Total revenues	15,030
Operating expenses
Costs of goods and services	(14,065)
Collaboration research and development services
Revenues
Total revenues	4,795	7,507
Collaboration research and development services | Third parties
Revenues
Total revenues	4,795	7,507
Research and development services
Revenues
Total revenues	261	240
Research and development services | Related parties
Revenues
Total revenues	261	240
Royalties
Revenues
Total revenues	5,817	2,045
Royalties | Third parties
Revenues
Total revenues	$ 5,817	$ 2,045

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net loss	$ (99,340)	$ (48,246)
Other comprehensive income/(loss)
Foreign currency translation gain/(loss)	1,084	(1,827)
Total comprehensive loss	(98,256)	(50,073)
Less: Comprehensive income attributable to non-controlling interests	(3,285)	(1,302)
Total comprehensive loss attributable to the Company	$ (101,541)	$ (51,375)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total Company's Shareholders' Equity	Ordinary Shares	Additional Paid-in Capital	Accumulated Losses	Accumulated Other Comprehensive (Loss)/Income	Non-controlling Interests	Total
Balance at Dec. 31, 2019	$ 288,012	$ 66,691	$ 514,904	$ (289,734)	$ (3,849)	$ 24,891	$ 312,903
Balance (in shares) at Dec. 31, 2019		666,906
Increase (Decrease) in Stockholders' Equity
Net (loss)/income	(49,694)			(49,694)		1,448	(48,246)
Issuance in relation to public offering	118,341	$ 2,366	115,975				118,341
Issuance in relation to public offering (in shares)		23,669
Issuance costs	(8,033)		(8,033)				(8,033)
Share-based compensation - share options	3,001		3,001			5	3,006
LTIP	5,217		5,217			(4)	5,213
Share-based compensation	8,218		8,218			1	8,219
LTIP-treasury shares acquired and held by Trustee	(12,904)		(12,904)				(12,904)
Dividend declared to a non-controlling shareholder of a subsidiary						(1,231)	(1,231)
Purchase of additional interests in a subsidiary of an equity investee (Note 7)	(139)		(52)	(83)	(4)	(35)	(174)
Transfer between reserves			17	(17)
Foreign currency translation adjustments	(1,681)				(1,681)	(146)	(1,827)
Balance at Jun. 30, 2020	342,120	$ 69,057	618,125	(339,528)	(5,534)	24,928	367,048
Balance (in shares) at Jun. 30, 2020		690,575
Balance at Dec. 31, 2019	288,012	$ 66,691	514,904	(289,734)	(3,849)	24,891	312,903
Balance (in shares) at Dec. 31, 2019		666,906
Balance at Dec. 31, 2020	484,116	$ 72,772	822,458	(415,591)	4,477	34,833	518,949
Balance (in shares) at Dec. 31, 2020		727,722
Increase (Decrease) in Stockholders' Equity
Net (loss)/income	(102,397)			(102,397)		3,057	(99,340)
Issuance in relation to public offering	534,667	$ 10,400	524,267				534,667
Issuance in relation to public offering (in shares)		104,000
Issuances in relation to private investment in public equity ("PIPE")	100,000	$ 1,639	98,361				100,000
Issuances in relation to private investment in public equity ("PIPE") (in shares)		16,393
Issuance costs	(26,952)		(26,952)				(26,952)
Issuances in relation to share option exercises	242	$ 40	202				242
Issuances in relation to share option exercises (in shares)		400
Share-based compensation - share options	7,913		7,913			12	7,925
LTIP	13,108		13,108			26	13,134
Share-based compensation	21,021		21,021			38	21,059
LTIP-treasury shares acquired and held by Trustee	(26,758)		(26,758)				(26,758)
Dividend declared to a non-controlling shareholder of a subsidiary						(9,256)	(9,256)
Transfer between reserves			8	(8)
Foreign currency translation adjustments	856				856	228	1,084
Balance at Jun. 30, 2021	$ 984,795	$ 84,851	$ 1,412,607	$ (517,996)	$ 5,333	$ 28,900	$ 1,013,695
Balance (in shares) at Jun. 30, 2021		848,515

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net cash used in operating activities	$ (71,319)	$ (28,376)
Investing activities
Purchases of property, plant and equipment	(8,914)	(4,058)
Deposits in short-term investments	(412,961)	(422,838)
Proceeds from short-term investments	249,500	287,775
Deposit received for divestment of an equity investee	15,912
Purchase of leasehold land	(355)
Refund of leasehold land deposit	930
Net cash used in investing activities	(155,888)	(139,121)
Financing activities
Proceeds from issuance of ordinary shares	634,909	118,341
Purchases of treasury shares	(26,758)	(12,904)
Dividends paid to a non-controlling shareholder of a subsidiary	(9,256)	(1,231)
Repayment of loan to a non-controlling shareholder of a subsidiary	(579)
Payment of issuance costs	(19,985)	(7,863)
Net cash generated from financing activities	578,331	96,343
Net increase/(decrease) in cash and cash equivalents	351,124	(71,154)
Effect of exchange rate changes on cash and cash equivalents	687	(63)
Net increase in cash and cash equivalents, including effect of exchange rate changes	351,811	(71,217)
Cash and cash equivalents
Cash and cash equivalents at beginning of period	235,630	121,157
Cash and cash equivalents at end of period	$ 587,441	$ 49,940

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2021
Organization and Nature of Business	1. Organization and Nature of Business HUTCHMED (China) Limited (formerly Hutchison China MediTech Limited) (the “Company”) and its subsidiaries (together the “Group”) are principally engaged in researching, developing, manufacturing and marketing pharmaceutical products. The Group and its equity investees have research and development facilities and manufacturing plants in the People’s Republic of China (the “PRC”) and sell their products mainly in the PRC, including Hong Kong. In addition, the Group has established international operations in the United States of America (the “U.S.”) and Europe. The Company's ordinary shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”) (listing completed in June 2021) and the AIM market of the London Stock Exchange, and its American depositary shares (“ADSs”) are traded on the Nasdaq Global Select Market. Liquidity As at June 30, 2021, the Group had accumulated losses of US$517,996,000 primarily due to its spending in drug research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at June 30, 2021, the Group had cash and cash equivalents of US$587,441,000, short-term investments of US$363,007,000 and unutilized bank borrowing facilities of US$69,359,000. Short-term investments comprised of bank deposits maturing over three months. The Group’s operating plan includes the continued receipt of dividends from certain of its equity investees. Dividends received from equity investees for the six months ended June 30, 2021 and 2020 were US$42,051,000 and US$35,321,000 respectively. Based on the Group’s operating plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months (the look-forward period used), and it is appropriate for the Group to prepare the condensed consolidated financial statements on a going concern basis.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies	2 . Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The interim unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The comparative year-end condensed balance sheet data was derived from the annual audited consolidated financial statements, but is condensed to the same degree as the interim condensed balance sheet data. The interim unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users have read or have access to the annual audited consolidated financial statements for the preceding fiscal year. The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the interim unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Recent Accounting Pronouncements Amendments that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group’s condensed consolidated financial statements. ​

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents	3 . Cash and Cash Equivalents ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Cash at bank and on hand (note (a)) ​ 113,922 ​ 87,828 Bank deposits maturing in three months or less (note (a)) ​ 473,519 ​ 147,802 ​ ​ 587,441 ​ 235,630 Denominated in: ​ ​ ​ ​ U.S. dollar (“US$”) (note (b)) ​ 440,309 ​ 164,201 Renminbi (“RMB”) (note (b)) ​ 74,061 ​ 64,258 UK Pound Sterling (“£”) (note (b)) ​ 124 ​ 954 Hong Kong dollar (“HK$”) ​ 72,909 ​ 5,907 Euro ​ 38 ​ 310 ​ ​ 587,441 ​ 235,630 ​ Notes: (a) The weighted average effective interest rate on bank deposits for the six months ended June 30, 2021 and the year ended December 31, 2020 was 0.73% per annum and 1.12% per annum respectively. (b) Certain cash and bank balances denominated in RMB, US$ and £ were deposited with banks in the PRC. The conversion of these balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

Short-term Investments

Short-term Investments	6 Months Ended
	Jun. 30, 2021
Short-term Investments
Short-term investments	4. Short-term Investments ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Bank deposits maturing over three months (note) ​ ​ Denominated in: US$ 358,776 187,961 RMB ​ 1,154 ​ 612 HK$ 3,077 10,973 ​ 363,007 199,546 ​ Note: The weighted average effective interest rate on bank deposits for the six months ended June 30, 2021 and the year ended December 31, 2020 was 0.26% per annum and 1.06% per annum respectively (with maturities ranging from 91 to 180 days).

Accounts Receivable-Third Parti

Accounts Receivable-Third Parties	6 Months Ended
	Jun. 30, 2021
Accounts Receivable-Third Parties	5. Accounts Receivable—Third Parties Accounts receivable from contracts with customers, net of allowance for credit losses, consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Accounts receivable, gross ​ 57,978 ​ 46,743 Allowance for credit losses ​ (25) ​ (95) Accounts receivable, net ​ 57,953 ​ 46,648 ​ Substantially all accounts receivable are denominated in RMB, US$ and HK$ and are due within one year from the end of the reporting periods. The carrying values of accounts receivable approximate their fair values due to their short-term maturities. Movements on the allowance for credit losses: ​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ (in US$’000) As at January 1 ​ 95 ​ 16 Increase in allowance for credit losses ​ 21 ​ 8 Decrease in allowance due to subsequent collection ​ (92) ​ (16) Exchange difference ​ 1 ​ — As at June 30 ​ 25 ​ 8 ​ An aging analysis based on the relevant invoice dates is as follows: ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Not later than 3 months 53,601 42,434 Between 3 months to 6 months 3,191 3,118 Between 6 months to 1 year 6 23 Later than 1 year 1,180 1,168 Accounts receivable, gross 57,978 46,743 ​

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventories	6 . Inventories Inventories, net of provision for excess and obsolete inventories, consisted of the following: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Raw materials ​ 8,202 ​ 4,502 Finished goods ​ 17,303 ​ 15,264 ​ ​ 25,505 ​ 19,766 ​ ​

Investments in Equity Investees

Investments in Equity Investees	6 Months Ended
	Jun. 30, 2021
Investments in Equity Investees	7 . Investments in Equity Investees Investments in equity investees consisted of the following: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”) (note) ​ 51,425 ​ 59,712 Shanghai Hutchison Pharmaceuticals Limited (“SHPL”) ​ 66,465 ​ 79,408 Other ​ 426 ​ 385 ​ ​ 118,316 ​ 139,505 ​ Note: In March 2021, the Group entered into a sale and purchase agreement (the “SPA”) with a third party (the “Buyer”) to sell its entire investment in HBYS with closing subject to regulatory approval in the PRC. As part of the divestment, the Group is entitled to (a) cash consideration of US$159.1 million, which includes US$15.9 million deposit collected upon the signing of the SPA and the remainder due upon closing; and (b) US$52.3 million related to distributions of prior year undistributed profits and a land bonus payment. The amounts to be received under (a) and (b) aggregate to US$211.4 million of which the amounts attributable to the Company are US$169.1 million. The equity investees are private companies and there are no quoted market prices available for their shares. Summarized financial information for the significant equity investees HBYS and SHPL, both under Other Ventures segment, is as follows: (i) Summarized balance sheets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS ​ SHPL ​ June 30, ​ December 31, ​ June 30, ​ December 31, ​ 2021 2020 2021 2020 ​ (in US$’000) Current assets ​ 194,035 ​ 177,888 ​ 161,508 ​ 175,965 Non-current assets ​ 93,361 ​ 95,731 ​ 93,211 ​ 93,361 Current liabilities ​ (154,871) ​ (137,179) ​ (119,821) ​ (109,873) Non-current liabilities ​ (28,673) ​ (16,034) ​ (8,123) ​ (6,739) Net assets ​ 103,852 ​ 120,406 ​ 126,775 ​ 152,714 Non-controlling interests ​ (1,002) ​ (982) ​ — ​ — ​ ​ 102,850 ​ 119,424 ​ 126,775 ​ 152,714 ​ (ii) Summarized statements of operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS (note (a)) ​ SHPL ​ ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 ​ ​ (in US$’000) Revenue 153,689 ​ 124,098 180,413 ​ 150,703 Gross profit 82,251 ​ 60,794 138,979 ​ 112,363 Interest income 66 ​ 81 751 ​ 396 Finance cost — ​ (5) — ​ — Profit before taxation 33,397 ​ 14,792 67,108 ​ 55,470 Income tax expense (note (b)) (4,807) ​ (2,386) (9,764) ​ (7,485) Net income ​ 28,590 ​ 12,406 ​ 57,344 ​ 47,985 Non-controlling interests ​ (14) ​ 207 ​ — ​ — Net income attributable to the shareholders of equity investee 28,576 ​ 12,613 ​ 57,344 ​ 47,985 ​ Notes: (a) In June 2020, HBYS entered into an agreement with the government to return the land use right for a plot of land in Guangzhou to the government (the “Land Compensation Agreement”) for cash consideration which aggregated to RMB 679.5 million (approximately US$ 103.1 million). In November 2020, HBYS completed all material obligations as stipulated in the Land Compensation Agreement and recognized land compensation of RMB 569.2 million (approximately US$ 86.1 million). In June 2021, HBYS received a completion confirmation from the government and became entitled to an additional land compensation bonus of RMB110.3 million (approximately US$17.0 million). HBYS recorded a gain before tax of RMB107.6 million (approximately US$16.6 million) after deducting costs of RMB2.7 million (approximately US$0.4 million). (b) The main entities within each of the HBYS and SHPL groups have been granted the High and New Technology Enterprise status (the latest renewal of this status covers the years from 2020 to 2022). These entities were eligible to use a preferential income tax rate of 15% for the six months ended June 30, 2021 on this basis. For the six months ended June 30, 2021 and 2020, other equity investees had net income of approximately US$79,000 and US$135,000 respectively. (iii) Reconciliation of summarized financial information Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS ​ SHPL ​ 2021 2020 2021 2020 ​ (in US$’000) Opening net assets after non-controlling interests as at January 1 ​ 119,424 ​ 44,541 ​ 152,714 ​ 146,759 Net income attributable to the shareholders of equity investee ​ 28,576 ​ 12,613 ​ 57,344 ​ 47,985 Purchase of additional interests in a subsidiary of an equity investee (note) ​ — ​ (347) ​ — ​ — Dividends declared ​ (46,538) ​ — ​ (84,103) ​ (42,308) Other comprehensive income/(loss) ​ 1,388 ​ (477) ​ 820 ​ (1,499) Closing net assets after non-controlling interests as at June ​ 102,850 ​ 56,330 ​ 126,775 ​ 150,937 Group’s share of net assets ​ 51,425 ​ 28,165 ​ 63,387 ​ 75,468 Goodwill ​ — ​ — ​ 3,078 ​ 2,821 Carrying amount of investments as at June 30 ​ 51,425 ​ 28,165 ​ 66,465 ​ 78,289 ​ Note: During the six months ended June 30, 2020, HBYS acquired an additional 30% interest in a subsidiary and after the acquisition, it became a wholly owned subsidiary of HBYS. The equity investees had the following capital commitments: ​ ​ ​ ​ ​ June 30, ​ 2021 ​ (in US$’000) Property, plant and equipment ​ ​ Contracted but not provided for ​ 2,654 ​

Accounts Payable

Accounts Payable	6 Months Ended
	Jun. 30, 2021
Accounts Payable	8. Accounts Payable ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Accounts payable 28,513 31,612 ​ Substantially all accounts payable are denominated in RMB and US$ and due within one year from the end of the reporting period. The carrying values of accounts payable approximate their fair values due to their short-term maturities. ​ An aging analysis based on the relevant invoice dates is as follows: ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Not later than 3 months 22,935 26,270 Between 3 months to 6 months 3,557 3,364 Between 6 months to 1 year 813 782 Later than 1 year 1,208 1,196 ​ ​ 28,513 31,612 ​

Other Payables, Accruals and Ad

Other Payables, Accruals and Advance Receipts	6 Months Ended
	Jun. 30, 2021
Other Payables, Accruals and Advance Receipts	9 . Other Payables, Accruals and Advance Receipts Other payables, accruals and advance receipts consisted of the following: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Accrued salaries and benefits ​ 28,527 ​ 21,982 Accrued research and development expenses ​ 86,477 ​ 72,697 Accrued selling and marketing expenses ​ 7,800 ​ 5,747 Accrued administrative and other general expenses ​ 12,587 ​ 10,319 Accrued issuance costs ​ 8,678 ​ 1,352 Deferred government grants ​ 6,889 ​ 374 Deposits ​ 1,636 ​ 1,408 Deposit received for divestment of HBYS (Note 7) ​ 15,912 ​ — Others ​ 13,104 ​ 7,003 ​ ​ 181,610 ​ 120,882 ​

Bank Borrowings

Bank Borrowings	6 Months Ended
	Jun. 30, 2021
Debt Instrument [Line Items]
Bank Borrowings	10 . Bank Borrowings Bank borrowings consisted of the following: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Current ​ 26,883 ​ — Non-current ​ — ​ 26,861 ​ ​ 26,883 ​ 26,861 ​ The weighted average interest rate for outstanding bank borrowings for the six months ended June 30, 2021 and the year ended December 31, 2020 was 1.10 % per annum and 1.89% per annum respectively. The carrying amounts of the Group’s bank borrowings were denominated in HK$. (i) 3-year revolving loan facility and 3-year term loan and revolving loan facilities In November 2018, the Group through its subsidiary, renewed a 3-year revolving loan facility with a bank in the amount of HK$234,000,000 (US$30,000,000) with an interest rate at the Hong Kong Interbank Offered Rate (“HIBOR”) plus 0.85% per annum. This credit facility is guaranteed by the Company. As at June 30, 2021 and December 31, 2020, no amount has been drawn from the revolving loan facility. In May 2019, the Group through its subsidiary, entered into a separate facility agreement with the bank for the provision of additional unsecured credit facilities in the aggregate amount of HK$400,000,000 (US$51,282,000). The 3-year credit facilities include (i) a HK$210,000,000 (US$26,923,000) term loan facility; and (ii) a HK$190,000,000 (US$24,359,000) revolving loan facility, both with an interest rate at HIBOR plus 0.85% per annum, and an upfront fee of HK$819,000 (US$105,000) on the term loan. These credit facilities are guaranteed by the Company. The term loan was drawn in October 2019 and is due in May 2022. As at June 30, 2021 and December 31, 2020, no amount has been drawn from the revolving loan facility. (ii) 2-year revolving loan facility In August 2020, the Group through its subsidiary, entered into a 2-year revolving loan facility with a bank in the amount of HK$117,000,000 (US$15,000,000) with an interest rate at HIBOR plus 4.5% per annum. This credit facility is guaranteed by the Company. As at June 30, 2021 and December 31, 2020, no amount has been drawn from the revolving loan facility. The Group’s bank borrowings are repayable as from the dates indicated as follows: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Not later than 1 year ​ 26,923 ​ — Between 1 to 2 years ​ — ​ 26,923 ​ ​ 26,923 ​ 26,923 ​ As at June 30, 2021 and December 31, 2020, the Group had unutilized bank borrowing facilities of HK$541,000,000 (US$69,359,000).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies	11. Commitments and Contingencies The Group had the following capital commitments: ​ ​ ​ ​ ​ June 30, ​ 2021 ​ (in US$’000) Property, plant and equipment ​ ​ Contracted but not provided for ​ 44,793 ​ Capital commitments for property, plant and equipment are mainly for construction of a factory in Shanghai. The Group does not have any other significant commitments or contingencies.

Ordinary Shares

Ordinary Shares	6 Months Ended
	Jun. 30, 2021
Ordinary Shares	12. Ordinary Shares As at June 30, 2021, the Company is authorized to issue 1,500,000,000 ordinary shares. On April 14, 2021, the Company issued 16,393,445 ordinary shares to a third party for gross proceeds of US$100.0 million through a PIPE. Issuance costs totaled US$0.1 million. On June 30, 2021, the Company issued 104,000,000 ordinary shares in a public offering on the HKEX for gross proceeds of US$534.7 million. Issuance costs totaled US$26.9 million. In connection with the public offering on the HKEX, the Company also granted an over-allotment option. Refer to Note 22. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Compensation
Share-based Compensation	13 . Share-based Compensation (i) Share-based Compensation of the Company The Company conditionally adopted a share option scheme on June 4, 2005 (as amended on March 21, 2007) and such scheme has a term of 10 years. It expired in 2016 and no further share options can be granted. Another share option scheme was conditionally adopted on April 24, 2015 (the “Hutchmed Share Option Scheme”). Pursuant to the Hutchmed Share Option Scheme, the Board of Directors of the Company may, at its discretion, offer any employees and directors (including Executive and Non-executive Directors but excluding Independent Non-executive Directors) of the Company, holding companies of the Company and any of their subsidiaries or affiliates, and subsidiaries or affiliates of the Company share options to subscribe for shares of the Company. As at June 30, 2021, the aggregate number of shares issuable under the Hutchmed Share Option Scheme was 50,613,268 ordinary shares and the aggregate number of shares issuable under the prior share option scheme which expired in 2016 was 716,180 ordinary shares. The Company will issue new shares to satisfy share option exercises. Additionally, the number of shares authorized but unissued was 651,484,340 ordinary shares. Share options granted are generally subject to a four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to the four-year vesting schedule, in general, vest 25% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 25% every subsequent year. However, certain share option grants may have a different vesting schedule as approved by the Board of Directors of the Company. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of eight A summary of the Company’s share option activity and related information is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Number of ​ Weighted average ​ remaining ​ Aggregate ​ ​ share ​ exercise price in ​ contractual life ​ intrinsic value ​ options £ per share (years) (in £’000) Outstanding at December 31, 2019 ​ 19,432,560 ​ 3.27 ​ 6.67 ​ 18,668 Granted ​ 15,437,080 ​ 3.71 ​ ​ ​ ​ Exercised ​ (480,780) ​ 0.96 ​ ​ ​ ​ Cancelled ​ (4,486,200) ​ 3.85 ​ ​ ​ ​ Expired ​ (741,670) ​ 4.62 ​ ​ ​ ​ Outstanding at December 31, 2020 ​ 29,160,990 ​ 3.40 ​ 7.21 ​ 35,654 Granted ​ 8,279,900 ​ 4.05 ​ ​ ​ ​ Exercised ​ (400,000) ​ 0.44 ​ ​ ​ ​ Cancelled ​ (817,800) ​ 4.31 ​ ​ ​ ​ Expired ​ (42,400) ​ 4.33 ​ ​ ​ ​ Outstanding at June 30, 2021 ​ 36,180,690 ​ 3.57 ​ 7.42 ​ 72,650 Vested and exercisable at December 31, 2020 ​ 11,529,280 ​ 2.73 ​ 4.57 ​ 21,864 Vested and exercisable at June 30, 2021 ​ 15,374,075 ​ 3.11 ​ 5.25 ​ 37,879 ​ In estimating the fair value of share options granted, the following assumptions were used in the Polynomial model for awards granted in the periods indicated: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Year Ended ​ June 30, 2021 December 31, 2020 ​ Weighted average grant date fair value of share options (in £ per share) 1.51 ​ 1.40 ​ Significant inputs into the valuation model (weighted average): ​ ​ ​ Exercise price (in £ per share) 4.05 ​ 3.71 ​ Share price at effective date of grant (in £ per share) 4.01 ​ 3.71 ​ Expected volatility (note (a)) 40.8 % 42.6 % Risk-free interest rate (note (b)) 1.68 % 0.59 % Contractual life of share options (in years) 10 ​ 10 ​ Expected dividend yield (note (c)) 0 % 0 % ​ Notes: (a) The Company calculated its expected volatility with reference to the historical volatility prior to the issuances of share options. (b) The risk-free interest rates reference the U.S. Treasury yield curves because the Company’s ADSs are currently listed on the NASDAQ and denominated in US$. (c) The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore uses an expected dividend yield of zero in the Polynomial model. The Company will issue new shares to satisfy share option exercises. The following table summarizes the Company’s share option exercises: ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Cash received from share option exercises ​ 242 — Total intrinsic value of share option exercises ​ 2,012 — ​ The Group recognizes compensation expense on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense for share options: ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Research and development expenses ​ 4,101 ​ 1,697 Selling and administrative expenses ​ 3,749 ​ 1,237 Cost of revenues ​ 75 ​ 72 ​ ​ 7,925 ​ 3,006 ​ As at June 30, 2021, the total unrecognized compensation cost was US$26,901,000, and will be recognized on a graded vesting approach over the weighted average remaining service period of 3.30 years. (ii) LTIP The Company grants awards under the LTIP to participating directors and employees, giving them a conditional right to receive ordinary shares of the Company or the equivalent ADSs (collectively the “Awarded Shares”) to be purchased by the Trustee up to a cash amount. Vesting will depend upon continued employment of the award holder with the Group and will otherwise be at the discretion of the Board of Directors of the Company. Additionally, some awards are subject to change based on annual performance targets prior to their determination date. LTIP awards prior to the determination date Performance targets vary by award, and may include targets for shareholder returns, free cash flows, revenues, net profit after taxes, the achievement of clinical and regulatory milestones and equity financings. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management’s assessment on the achievement of the performance target has been assigned to calculate the amount to be recognized as an expense over the requisite period with a corresponding entry to liability. LTIP awards after the determination date Upon the determination date, the Company will pay a determined monetary amount, up to the maximum cash amount based on the actual achievement of the performance target specified in the award, to the Trustee to purchase the Awarded Shares. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid-in capital, as an equity-settled award. If the performance target is not achieved, no Awarded Shares of the Company will be purchased and the amount previously recorded in the liability will be reversed through share-based compensation expense. Granted awards under the LTIP are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Maximum cash ​ ​ ​ ​ amount per annum ​ Covered ​ Performance target Grant date ​ (in US$ millions) ​ financial years ​ determination date April 20, 2020 ​ 5.3 ​ 2019 ​ note (d) April 20, 2020 ​ 37.4 ​ 2020 ​ note (a) April 20, 2020 ​ 1.9 ​ note (b) ​ note (b) April 20, 2020 ​ 0.2 ​ note (c) ​ note (c) August 12, 2020 ​ 2.1 ​ 2020 ​ note (a) August 12, 2020 ​ 0.3 ​ note (b) ​ note (b) March 26, 2021 ​ 57.3 ​ 2021 ​ note (a) ​ Notes: (a) The annual performance target determination date is the date of the announcement of the Group’s annual results for the covered financial year and vesting occurs two business days after the announcement of the Group’s annual results for the financial year falling two years after the covered financial year to which the LTIP award relates. (b) This award does not stipulate performance targets and is subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant. (c) This award does not stipulate performance targets and will be vested on the first anniversary of the date of grant. (d) This award does not stipulate performance targets and vesting occurs two business days after the announcement of the Group’s annual results for the financial year falling two years after the covered financial year to which the LTIP award relates. The Trustee has been set up solely for the purpose of purchasing and holding the Awarded Shares during the vesting period on behalf of the Company using funds provided by the Company. On the determination date, if any, the Company will determine the cash amount, based on the actual achievement of each annual performance target, for the Trustee to purchase the Awarded Shares. The Awarded Shares will then be held by the Trustee until they are vested. The Trustee’s assets include treasury shares and funds for additional treasury shares, trustee fees and expenses. The number of treasury shares (in the form of ordinary shares or ADSs of the Company) held by the Trustee were as follows: ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Cost ​ treasury shares (in US$’000) As at December 31, 2019 ​ 941,310 ​ 6,079 Purchased ​ 3,281,920 ​ 12,904 Vested ​ (712,555) ​ (4,828) As at December 31, 2020 ​ 3,510,675 ​ 14,155 Purchased ​ 4,821,680 ​ 26,758 Vested ​ (271,595) ​ (1,416) As at June 30, 2021 ​ 8,060,760 ​ 39,497 ​ For the six months ended June 30, 2021 and 2020, US$2,532,000 and US$430,000 of the LTIP awards were forfeited respectively. The following table presents the share-based compensation expenses recognized for LTIP awards: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Research and development expenses 6,725 3,145 Selling and administrative expenses 3,542 756 Cost of revenues ​ 165 ​ 60 ​ ​ 10,432 ​ 3,961 Recorded with a corresponding credit to: ​ ​ ​ ​ Liability ​ 5,814 ​ 2,840 Additional paid-in capital ​ 4,618 ​ 1,121 ​ 10,432 3,961 ​ For the six months ended June 30, 2021 and 2020, US$8,516,000 and US$4,092,000 were reclassified from liability to additional paid-in capital respectively upon LTIP awards reaching the determination date. As at June 30, 2021 and December 31, 2020, US$4,387,000 and US$7,089,000 were recorded as liabilities respectively for LTIP awards prior to the determination date. As at June 30, 2021, the total unrecognized compensation cost was approximately US$65,893,000, which considers expected performance targets and the amount expected to vest, and will be recognized over the requisite periods.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2021
Revenues	14. Revenues The following table presents disaggregated revenue, with sales of goods recognized at a point-in-time and provision of services recognized over time: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Oncology/ ​ ​ ​ ​ Immunology ​ Other Ventures ​ Total ​ ​ (in US$’000) Goods—Marketed Products 16,948 — 16,948 —Distribution — 114,511 114,511 Services—Commercialization—Marketed Products 15,030 — 15,030 —Collaboration Research and Development ​ 4,795 ​ — ​ 4,795 —Research and Development ​ 261 ​ — ​ 261 Royalties ​ 5,817 ​ — ​ 5,817 ​ 42,851 114,511 157,362 ​ Third parties 42,590 112,200 154,790 Related parties (Note 16(i)) 261 2,311 2,572 ​ ​ 42,851 ​ 114,511 ​ 157,362 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ Oncology/ ​ ​ ​ Immunology ​ Other Ventures ​ Total ​ ​ (in US$’000) Goods—Marketed Products 6,600 — 6,600 —Distribution ​ — ​ 90,373 ​ 90,373 Services—Collaboration Research and Development 7,507 — 7,507 —Research and Development ​ 240 ​ — ​ 240 Royalties 2,045 — 2,045 ​ ​ 16,392 ​ 90,373 ​ 106,765 ​ ​ ​ ​ ​ ​ ​ Third parties 16,152 88,289 104,441 Related parties (Note 16(i)) 240 2,084 2,324 ​ ​ 16,392 ​ 90,373 ​ 106,765 ​

Research and Development Expens

Research and Development Expenses	6 Months Ended
	Jun. 30, 2021
Research and Development Expenses	15 . Research and Development Expenses Research and development expenses are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Clinical trial related costs ​ 72,721 ​ 40,986 Personnel compensation and related costs ​ 41,056 ​ 29,356 Other research and development expenses ​ 9,273 ​ 3,632 ​ ​ 123,050 ​ 73,974 ​ The Group has entered into multiple collaborative arrangements under ASC 808 to evaluate the combination of the Group’s drug compounds with the collaboration partners' drug compounds. For the six months ended June 30, 2021 and 2020, the Group has incurred research and development expenses of US$6,146,000 and US$2,360,000 respectively, related to such collaborative arrangements.

Significant Transactions with R

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries	6 Months Ended
	Jun. 30, 2021
Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries	16. Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries The Group has the following significant transactions with related parties and non-controlling shareholders of subsidiaries, which were carried out in the normal course of business at terms determined and agreed by the relevant parties: (i) Transactions with related parties: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Sales to: ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison Holdings Limited (“CK Hutchison”) ​ 2,311 ​ 2,084 Revenue from research and development services from: ​ ​ ​ ​ An equity investee ​ 261 ​ 240 Purchases from: ​ ​ ​ ​ Equity investees ​ 1,954 ​ 1,887 Rendering of marketing services from: ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison ​ 186 ​ 152 Rendering of management services from: ​ ​ ​ ​ An indirect subsidiary of CK Hutchison ​ 485 ​ 478 ​ (ii) Balances with related parties included in: ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Accounts receivable—related parties ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison (note (a)) ​ 664 ​ 1,222 An equity investee (note (a)) ​ 261 ​ — ​ ​ 925 ​ 1,222 Amounts due from related parties ​ ​ ​ ​ Equity investees (note (a) and (b)) ​ 24,225 ​ 1,142 Amounts due to a related party ​ ​ ​ ​ An indirect subsidiary of CK Hutchison (note (c)) ​ 428 ​ 401 Other deferred income ​ ​ ​ ​ An equity investee (note (d)) ​ 841 ​ 950 ​ Notes: (a) Balances with related parties are unsecured, repayable on demand and interest-free. The carrying values of balances with related parties approximate their fair values due to their short-term maturities. (b) As at June 30, 2021 and December 31, 2020, the Group had dividend receivables from an equity investee of US$ 23,077,000 and nil respectively. (c) Amounts due to an indirect subsidiary of CK Hutchison are unsecured, repayable on demand and interest-bearing if not settled within one month . (d) Other d eferred income represents amount s recognized from granting of promotion and marketing rights . (iii) Transactions with non-controlling shareholders of subsidiaries: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Sales 20,144 16,784 Purchases 7,211 6,625 Dividend paid 9,256 1,231 ​ (iv) Balances with non-controlling shareholders of subsidiaries included in: ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Accounts receivable 9,051 6,184 Accounts payable 5,835 4,856 Other non-current liabilities Loan — 579 ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Taxes	17 . Income Taxes ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Current tax ​ ​ ​ ​ HK ​ 226 ​ 232 PRC ​ 2,184 ​ 48 U.S. and others ​ 231 ​ 530 Total current tax ​ 2,641 ​ 810 Deferred income tax ​ (782) ​ 1,222 Income tax expense ​ 1,859 ​ 2,032 ​ The reconciliation of the Group’s reported income tax expense to the theoretical tax amount that would arise using the tax rate of the Company against the Group’s loss before income taxes and equity in earnings of equity investees is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Loss before income taxes and equity in earnings of equity investees ​ (140,447) ​ (76,580) Tax calculated at the statutory tax rate of the Company ​ (23,174) ​ (12,636) Tax effects of: ​ ​ ​ ​ Different tax rates applicable in different jurisdictions ​ 3,585 ​ 1,431 Tax valuation allowance ​ 28,634 ​ 16,178 Preferential tax rate difference ​ (253) ​ (119) Preferential tax deduction and credits ​ (11,288) ​ (4,678) Expenses not deductible for tax purposes ​ 3,034 ​ 1,618 Utilization of previously unrecognized tax losses ​ (864) ​ (152) Withholding tax on undistributed earnings of PRC entities ​ 2,360 ​ 1,513 Income not subject to tax ​ (436) ​ (552) Others ​ 261 ​ (571) Income tax expense ​ 1,859 ​ 2,032 ​

Losses Per Share

Losses Per Share	6 Months Ended
	Jun. 30, 2021
Losses Per Share	18. Losses Per Share (i) Basic losses per share Basic losses per share is calculated by dividing the net loss attributable to the Company by the weighted average number of outstanding ordinary shares in issue during the period. Treasury shares held by the Trustee are excluded from the weighted average number of outstanding ordinary shares in issue for purposes of calculating basic losses per share. ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 Weighted average number of outstanding ordinary shares in issue 729,239,181 685,285,841 Net loss attributable to the Company (US$’000) (102,397) (49,694) Losses per share attributable to the Company (US$ per share) (0.14) (0.07) ​ (ii) Diluted losses per share Diluted losses per share is calculated by dividing net loss attributable to the Company by the weighted average number of outstanding ordinary shares in issue and dilutive ordinary share equivalents outstanding during the period. Dilutive ordinary share equivalents include shares issuable upon the exercise or settlement of share options, LTIP awards and warrants issued by the Company using the treasury stock method. For the six months ended June 30, 2021 and 2020, the share options, LTIP awards and warrants issued by the Company were not included in the calculation of diluted losses per share because of their anti-dilutive effect. Therefore, diluted losses per share were equal to basic losses per share for the six months ended June 30, 2021 and 2020.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2021
Segment Reporting	19 . Segment Reporting The Group’s operating segments are as follows: (i) Oncology/Immunology: focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Oncology/Immunology is further segregated into two core business areas: (a) R&D: comprises research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations; and (b) Marketed Products: comprises the sales, marketing, manufacture and distribution of drugs developed from research and development activities. (ii) Other Ventures: comprises other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products. The performance of the reportable segments is assessed based on segment operating (loss)/profit. The segment information is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Revenue from external customers ​ 5,056 ​ — ​ 5,056 ​ 37,795 ​ 42,851 ​ 114,511 ​ — ​ 157,362 Interest income ​ 523 ​ 2 ​ 525 ​ — ​ 525 ​ 145 ​ 361 ​ 1,031 Equity in earnings of equity investees, net of tax ​ 40 ​ — ​ 40 ​ — ​ 40 ​ 42,926 ​ — ​ 42,966 Segment operating (loss)/profit ​ (69,961) ​ (62,341) ​ (132,302) ​ 4,707 ​ (127,595) ​ 44,663 ​ (14,307) ​ (97,239) Interest expense ​ — ​ — ​ — ​ — ​ — ​ — ​ 242 ​ 242 Income tax expense/(credit) ​ 109 ​ (1,492) ​ (1,383) ​ 571 ​ (812) ​ 265 ​ 2,406 ​ 1,859 Net (loss)/income attributable to the Company ​ (69,911) ​ (60,699) ​ (130,610) ​ 3,650 ​ (126,960) ​ 41,263 ​ (16,700) ​ (102,397) Depreciation/amortization ​ 3,198 ​ 67 ​ 3,265 ​ — ​ 3,265 ​ 160 ​ 97 ​ 3,522 Additions to non-current assets (other than financial instruments and deferred tax assets) ​ 10,183 ​ 466 ​ 10,649 ​ — ​ 10,649 ​ 632 ​ 66 ​ 11,347 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Total assets ​ 143,099 ​ 7,751 ​ 150,850 ​ 24,942 ​ 175,792 ​ 215,563 ​ 881,534 ​ 1,272,889 Property, plant and equipment ​ 27,160 ​ 853 ​ 28,013 ​ — ​ 28,013 ​ 713 ​ 442 ​ 29,168 Right-of-use assets ​ 4,455 ​ 1,284 ​ 5,739 ​ — ​ 5,739 ​ 2,686 ​ 1,098 ​ 9,523 Leasehold land ​ 13,092 ​ — ​ 13,092 ​ — ​ 13,092 ​ — ​ — ​ 13,092 Goodwill ​ — ​ — ​ — ​ — ​ — ​ 3,332 ​ — ​ 3,332 Other intangible asset ​ — ​ — ​ — ​ — ​ — ​ 194 ​ — ​ 194 Investments in equity investees ​ 426 ​ — ​ 426 ​ — ​ 426 ​ 117,890 ​ — ​ 118,316 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Revenue from external customers ​ 7,747 ​ — ​ 7,747 ​ 8,645 ​ 16,392 ​ 90,373 ​ — ​ 106,765 Interest income ​ 114 ​ — ​ 114 ​ — ​ 114 ​ 71 ​ 1,732 ​ 1,917 Equity in earnings of equity investees, net of tax ​ 68 ​ — ​ 68 ​ — ​ 68 ​ 30,298 ​ — ​ 30,366 Segment operating (loss)/profit ​ (53,454) ​ (19,923) ​ (73,377) ​ 5,048 ​ (68,329) ​ 32,300 ​ (9,674) ​ (45,703) Interest expense ​ — ​ — ​ — ​ — ​ — ​ — ​ 511 ​ 511 Income tax expense ​ 167 ​ 145 ​ 312 ​ — ​ 312 ​ 156 ​ 1,564 ​ 2,032 Net (loss)/income attributable to the Company ​ (53,590) ​ (20,018) ​ (73,608) ​ 5,035 ​ (68,573) ​ 30,438 ​ (11,559) ​ (49,694) Depreciation/amortization ​ 2,629 ​ 58 ​ 2,687 ​ — ​ 2,687 ​ 141 ​ 95 ​ 2,923 Additions to non-current assets (other than financial instruments and deferred tax assets) ​ 4,241 ​ 21 ​ 4,262 ​ — ​ 4,262 ​ 140 ​ 13 ​ 4,415 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Total assets ​ 127,637 ​ 9,957 ​ 137,594 ​ 5,728 ​ 143,322 ​ 231,234 ​ 349,562 ​ 724,118 Property, plant and equipment ​ 22,554 ​ 454 ​ 23,008 ​ — ​ 23,008 ​ 688 ​ 474 ​ 24,170 Right-of-use assets ​ 2,782 ​ 1,375 ​ 4,157 ​ — ​ 4,157 ​ 2,582 ​ 1,277 ​ 8,016 Leasehold land ​ 13,121 ​ — ​ 13,121 ​ — ​ 13,121 ​ — ​ — ​ 13,121 Goodwill ​ — ​ — ​ — ​ — ​ — ​ 3,307 ​ — ​ 3,307 Other intangible asset ​ — ​ — ​ — ​ — ​ — ​ 227 ​ — ​ 227 Investments in equity investees ​ 385 ​ — ​ 385 ​ — ​ 385 ​ 139,120 ​ — ​ 139,505 ​ Revenue from external customers is after elimination of inter-segment sales. Sales between segments are carried out at mutually agreed terms. The amount eliminated attributable to sales between PRC and U.S. and others under the Oncology/Immunology segment was US$14,837,000 and US$6,554,000 for the six months ended June 30, 2021 and 2020 respectively. There was one customer under Oncology/Immunology segment (with revenue of US$30,981,000) and one customer under Other Ventures segment (with aggregate revenue of US$20,144,000), which accounted for over 10% of the Group’s revenue for the six months ended June 30, 2021. There was one customer under Oncology/Immunology segment (with revenue of US$10,846,000) and one customer under Other Ventures segment (with revenue of US$16,784,000), which accounted for over 10% of the Group’s revenue for the six months ended June 30, 2020. Unallocated expenses mainly represent corporate expenses which include corporate employee benefit expenses and the relevant share-based compensation expenses. Unallocated assets mainly comprise cash and cash equivalents and short-term investments. A reconciliation of segment operating loss to net loss is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Segment operating loss ​ (97,239) ​ (45,703) Interest expense ​ (242) ​ (511) Income tax expense ​ (1,859) ​ (2,032) Net loss ​ (99,340) ​ (48,246) ​

Note to Condensed Consolidated

Note to Condensed Consolidated Statements of Cash Flows	6 Months Ended
	Jun. 30, 2021
Note to Condensed Consolidated Statements of Cash Flows	20 . Note to Condensed Consolidated Statements of Cash Flows Reconciliation of net loss for the period to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Net loss ​ (99,340) ​ (48,246) Adjustments to reconcile net loss to net cash used in operating activities ​ ​ ​ ​ Depreciation and amortization ​ 3,522 ​ 2,923 Share-based compensation expense—share options ​ 7,925 ​ 3,006 Share-based compensation expense—LTIP ​ 10,432 ​ 3,961 Equity in earnings of equity investees, net of tax ​ (42,966) ​ (30,366) Dividends received from equity investees ​ 42,051 ​ 35,321 Changes in right-of-use assets ​ (1,468) ​ 205 Other adjustments ​ (2,464) ​ (740) Changes in working capital ​ ​ ​ ​ Accounts receivable—third parties ​ (11,234) ​ (3,205) Inventories ​ (5,669) ​ 1,171 Accounts payable ​ (3,099) ​ 1,910 Other payables, accruals and advance receipts ​ 33,836 ​ 7,313 Lease liabilities ​ 902 ​ (334) Other changes in working capital ​ (3,747) ​ (1,295) Total changes in working capital ​ 10,989 ​ 5,560 Net cash used in operating activities ​ (71,319) ​ (28,376) ​

Litigation

Litigation	6 Months Ended
	Jun. 30, 2021
Litigation	21 . Litigation From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a material adverse effect on the Group’s results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties and the Group’s view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group’s financial position and results of operations for the periods in which the unfavorable outcome occurs, and potentially in future periods. On May 17, 2019, Luye Pharma Hong Kong Ltd. (“Luye”) issued a notice to the Group purporting to terminate a distribution agreement that granted the Group exclusive commercial rights to Seroquel in the PRC for failure to meet a pre-specified target. The Group disagrees with this assertion and believes that Luye have no basis for termination. As a result, the Group commenced confidential legal proceedings in 2019 in order to seek damages. As at June 30, 2021, the legal proceedings are still in progress. Accordingly, no adjustment has been made to Seroquel-related balances as at June 30, 2021, including accounts receivable, long-term prepayment, accounts payable and other payables of US$1.2 million, US$0.8 million, US$1.0 million and US$1.3 million respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events	22. Subsequent Events The Group evaluated subsequent events through July 28, 2021, which is the date when the interim unaudited condensed consolidated financial statements were issued. On July 12, 2021, the over-allotment option in connection with the Company’s public offering on the HKEX was exercised in full. The Company issued 15,600,000 ordinary shares at an exercise price of HK$40.10 per ordinary shares for gross proceeds of US$80.2 million.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The interim unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The comparative year-end condensed balance sheet data was derived from the annual audited consolidated financial statements, but is condensed to the same degree as the interim condensed balance sheet data. The interim unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users have read or have access to the annual audited consolidated financial statements for the preceding fiscal year. The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the interim unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Amendments that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group’s condensed consolidated financial statements.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of cash and cash equivalents	​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Cash at bank and on hand (note (a)) ​ 113,922 ​ 87,828 Bank deposits maturing in three months or less (note (a)) ​ 473,519 ​ 147,802 ​ ​ 587,441 ​ 235,630 Denominated in: ​ ​ ​ ​ U.S. dollar (“US$”) (note (b)) ​ 440,309 ​ 164,201 Renminbi (“RMB”) (note (b)) ​ 74,061 ​ 64,258 UK Pound Sterling (“£”) (note (b)) ​ 124 ​ 954 Hong Kong dollar (“HK$”) ​ 72,909 ​ 5,907 Euro ​ 38 ​ 310 ​ ​ 587,441 ​ 235,630 ​ Notes: (a) The weighted average effective interest rate on bank deposits for the six months ended June 30, 2021 and the year ended December 31, 2020 was 0.73% per annum and 1.12% per annum respectively. (b) Certain cash and bank balances denominated in RMB, US$ and £ were deposited with banks in the PRC. The conversion of these balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

Short-term Investments (Tables)

Short-term Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Short-term Investments
Schedule of short-term investments	​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Bank deposits maturing over three months (note) ​ ​ Denominated in: US$ 358,776 187,961 RMB ​ 1,154 ​ 612 HK$ 3,077 10,973 ​ 363,007 199,546 ​ Note: The weighted average effective interest rate on bank deposits for the six months ended June 30, 2021 and the year ended December 31, 2020 was 0.26% per annum and 1.06% per annum respectively (with maturities ranging from 91 to 180 days).

Accounts Receivable-Third Par_2

Accounts Receivable-Third Parties (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ ​ (in US$’000) Accounts receivable, gross ​ 57,978 ​ 46,743 Allowance for credit losses ​ (25) ​ (95) Accounts receivable, net ​ 57,953 ​ 46,648
Schedule of movements on the allowance for credit losses	​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ (in US$’000) As at January 1 ​ 95 ​ 16 Increase in allowance for credit losses ​ 21 ​ 8 Decrease in allowance due to subsequent collection ​ (92) ​ (16) Exchange difference ​ 1 ​ — As at June 30 ​ 25 ​ 8
Schedule of aging analysis based on the relevant invoice dates	​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Not later than 3 months 53,601 42,434 Between 3 months to 6 months 3,191 3,118 Between 6 months to 1 year 6 23 Later than 1 year 1,180 1,168 Accounts receivable, gross 57,978 46,743

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of inventories, net of provision for excess and obsolete inventories	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Raw materials ​ 8,202 ​ 4,502 Finished goods ​ 17,303 ​ 15,264 ​ ​ 25,505 ​ 19,766 ​

Investments in Equity Investe_2

Investments in Equity Investees (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of composition of equity investees	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”) (note) ​ 51,425 ​ 59,712 Shanghai Hutchison Pharmaceuticals Limited (“SHPL”) ​ 66,465 ​ 79,408 Other ​ 426 ​ 385 ​ ​ 118,316 ​ 139,505 ​ Note: In March 2021, the Group entered into a sale and purchase agreement (the “SPA”) with a third party (the “Buyer”) to sell its entire investment in HBYS with closing subject to regulatory approval in the PRC. As part of the divestment, the Group is entitled to (a) cash consideration of US$159.1 million, which includes US$15.9 million deposit collected upon the signing of the SPA and the remainder due upon closing; and (b) US$52.3 million related to distributions of prior year undistributed profits and a land bonus payment. The amounts to be received under (a) and (b) aggregate to US$211.4 million of which the amounts attributable to the Company are US$169.1 million.
Summarized balance sheets for significant equity investees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS ​ SHPL ​ June 30, ​ December 31, ​ June 30, ​ December 31, ​ 2021 2020 2021 2020 ​ (in US$’000) Current assets ​ 194,035 ​ 177,888 ​ 161,508 ​ 175,965 Non-current assets ​ 93,361 ​ 95,731 ​ 93,211 ​ 93,361 Current liabilities ​ (154,871) ​ (137,179) ​ (119,821) ​ (109,873) Non-current liabilities ​ (28,673) ​ (16,034) ​ (8,123) ​ (6,739) Net assets ​ 103,852 ​ 120,406 ​ 126,775 ​ 152,714 Non-controlling interests ​ (1,002) ​ (982) ​ — ​ — ​ ​ 102,850 ​ 119,424 ​ 126,775 ​ 152,714
Summarized statements of operations for significant equity investees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS (note (a)) ​ SHPL ​ ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 ​ ​ (in US$’000) Revenue 153,689 ​ 124,098 180,413 ​ 150,703 Gross profit 82,251 ​ 60,794 138,979 ​ 112,363 Interest income 66 ​ 81 751 ​ 396 Finance cost — ​ (5) — ​ — Profit before taxation 33,397 ​ 14,792 67,108 ​ 55,470 Income tax expense (note (b)) (4,807) ​ (2,386) (9,764) ​ (7,485) Net income ​ 28,590 ​ 12,406 ​ 57,344 ​ 47,985 Non-controlling interests ​ (14) ​ 207 ​ — ​ — Net income attributable to the shareholders of equity investee 28,576 ​ 12,613 ​ 57,344 ​ 47,985 ​ Notes: (a) In June 2020, HBYS entered into an agreement with the government to return the land use right for a plot of land in Guangzhou to the government (the “Land Compensation Agreement”) for cash consideration which aggregated to RMB 679.5 million (approximately US$ 103.1 million). In November 2020, HBYS completed all material obligations as stipulated in the Land Compensation Agreement and recognized land compensation of RMB 569.2 million (approximately US$ 86.1 million). In June 2021, HBYS received a completion confirmation from the government and became entitled to an additional land compensation bonus of RMB110.3 million (approximately US$17.0 million). HBYS recorded a gain before tax of RMB107.6 million (approximately US$16.6 million) after deducting costs of RMB2.7 million (approximately US$0.4 million). (b) The main entities within each of the HBYS and SHPL groups have been granted the High and New Technology Enterprise status (the latest renewal of this status covers the years from 2020 to 2022). These entities were eligible to use a preferential income tax rate of 15% for the six months ended June 30, 2021 on this basis.
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HBYS ​ SHPL ​ 2021 2020 2021 2020 ​ (in US$’000) Opening net assets after non-controlling interests as at January 1 ​ 119,424 ​ 44,541 ​ 152,714 ​ 146,759 Net income attributable to the shareholders of equity investee ​ 28,576 ​ 12,613 ​ 57,344 ​ 47,985 Purchase of additional interests in a subsidiary of an equity investee (note) ​ — ​ (347) ​ — ​ — Dividends declared ​ (46,538) ​ — ​ (84,103) ​ (42,308) Other comprehensive income/(loss) ​ 1,388 ​ (477) ​ 820 ​ (1,499) Closing net assets after non-controlling interests as at June ​ 102,850 ​ 56,330 ​ 126,775 ​ 150,937 Group’s share of net assets ​ 51,425 ​ 28,165 ​ 63,387 ​ 75,468 Goodwill ​ — ​ — ​ 3,078 ​ 2,821 Carrying amount of investments as at June 30 ​ 51,425 ​ 28,165 ​ 66,465 ​ 78,289 ​ Note: During the six months ended June 30, 2020, HBYS acquired an additional 30% interest in a subsidiary and after the acquisition, it became a wholly owned subsidiary of HBYS.
Schedule of equity investees capital commitments	​ ​ ​ ​ ​ June 30, ​ 2021 ​ (in US$’000) Property, plant and equipment ​ ​ Contracted but not provided for ​ 2,654

Accounts Payable (Tables)

Accounts Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of accounts payable	​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Accounts payable 28,513 31,612 ​
Schedule of aging analysis based on the relevant invoice dates	​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Not later than 3 months 22,935 26,270 Between 3 months to 6 months 3,557 3,364 Between 6 months to 1 year 813 782 Later than 1 year 1,208 1,196 ​ ​ 28,513 31,612

Other Payables, Accruals and _2

Other Payables, Accruals and Advance Receipts (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of other payables, accruals and advance receipts	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Accrued salaries and benefits ​ 28,527 ​ 21,982 Accrued research and development expenses ​ 86,477 ​ 72,697 Accrued selling and marketing expenses ​ 7,800 ​ 5,747 Accrued administrative and other general expenses ​ 12,587 ​ 10,319 Accrued issuance costs ​ 8,678 ​ 1,352 Deferred government grants ​ 6,889 ​ 374 Deposits ​ 1,636 ​ 1,408 Deposit received for divestment of HBYS (Note 7) ​ 15,912 ​ — Others ​ 13,104 ​ 7,003 ​ ​ 181,610 ​ 120,882

Bank Borrowings (Tables)

Bank Borrowings (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Instrument [Line Items]
Schedule of bank borrowings	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Current ​ 26,883 ​ — Non-current ​ — ​ 26,861 ​ ​ 26,883 ​ 26,861 ​
Schedule of maturities of bank borrowings	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Not later than 1 year ​ 26,923 ​ — Between 1 to 2 years ​ — ​ 26,923 ​ ​ 26,923 ​ 26,923 ​

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of capital commitments	​ ​ ​ ​ ​ June 30, ​ 2021 ​ (in US$’000) Property, plant and equipment ​ ​ Contracted but not provided for ​ 44,793

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Hutchmed Share Option Scheme
Share-based Compensation
Schedule of share option activity and related information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Number of ​ Weighted average ​ remaining ​ Aggregate ​ ​ share ​ exercise price in ​ contractual life ​ intrinsic value ​ options £ per share (years) (in £’000) Outstanding at December 31, 2019 ​ 19,432,560 ​ 3.27 ​ 6.67 ​ 18,668 Granted ​ 15,437,080 ​ 3.71 ​ ​ ​ ​ Exercised ​ (480,780) ​ 0.96 ​ ​ ​ ​ Cancelled ​ (4,486,200) ​ 3.85 ​ ​ ​ ​ Expired ​ (741,670) ​ 4.62 ​ ​ ​ ​ Outstanding at December 31, 2020 ​ 29,160,990 ​ 3.40 ​ 7.21 ​ 35,654 Granted ​ 8,279,900 ​ 4.05 ​ ​ ​ ​ Exercised ​ (400,000) ​ 0.44 ​ ​ ​ ​ Cancelled ​ (817,800) ​ 4.31 ​ ​ ​ ​ Expired ​ (42,400) ​ 4.33 ​ ​ ​ ​ Outstanding at June 30, 2021 ​ 36,180,690 ​ 3.57 ​ 7.42 ​ 72,650 Vested and exercisable at December 31, 2020 ​ 11,529,280 ​ 2.73 ​ 4.57 ​ 21,864 Vested and exercisable at June 30, 2021 ​ 15,374,075 ​ 3.11 ​ 5.25 ​ 37,879 ​
Schedule of assumptions used in estimating fair value of share options granted	​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Year Ended ​ June 30, 2021 December 31, 2020 ​ Weighted average grant date fair value of share options (in £ per share) 1.51 ​ 1.40 ​ Significant inputs into the valuation model (weighted average): ​ ​ ​ Exercise price (in £ per share) 4.05 ​ 3.71 ​ Share price at effective date of grant (in £ per share) 4.01 ​ 3.71 ​ Expected volatility (note (a)) 40.8 % 42.6 % Risk-free interest rate (note (b)) 1.68 % 0.59 % Contractual life of share options (in years) 10 ​ 10 ​ Expected dividend yield (note (c)) 0 % 0 % ​ Notes: (a) The Company calculated its expected volatility with reference to the historical volatility prior to the issuances of share options. (b) The risk-free interest rates reference the U.S. Treasury yield curves because the Company’s ADSs are currently listed on the NASDAQ and denominated in US$. (c) The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore uses an expected dividend yield of zero in the Polynomial model.
Schedule of share option exercises	​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Cash received from share option exercises ​ 242 — Total intrinsic value of share option exercises ​ 2,012 —
Schedule of share-based compensation expenses	​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Research and development expenses ​ 4,101 ​ 1,697 Selling and administrative expenses ​ 3,749 ​ 1,237 Cost of revenues ​ 75 ​ 72 ​ ​ 7,925 ​ 3,006 ​
LTIP
Share-based Compensation
Schedule of granted awards	​ ​ ​ ​ ​ ​ ​ ​ ​ Maximum cash ​ ​ ​ ​ amount per annum ​ Covered ​ Performance target Grant date ​ (in US$ millions) ​ financial years ​ determination date April 20, 2020 ​ 5.3 ​ 2019 ​ note (d) April 20, 2020 ​ 37.4 ​ 2020 ​ note (a) April 20, 2020 ​ 1.9 ​ note (b) ​ note (b) April 20, 2020 ​ 0.2 ​ note (c) ​ note (c) August 12, 2020 ​ 2.1 ​ 2020 ​ note (a) August 12, 2020 ​ 0.3 ​ note (b) ​ note (b) March 26, 2021 ​ 57.3 ​ 2021 ​ note (a) ​ Notes: (a) The annual performance target determination date is the date of the announcement of the Group’s annual results for the covered financial year and vesting occurs two business days after the announcement of the Group’s annual results for the financial year falling two years after the covered financial year to which the LTIP award relates. (b) This award does not stipulate performance targets and is subject to a vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant. (c) This award does not stipulate performance targets and will be vested on the first anniversary of the date of grant. (d) This award does not stipulate performance targets and vesting occurs two business days after the announcement of the Group’s annual results for the financial year falling two years after the covered financial year to which the LTIP award relates.
Schedule of treasury shares (in the form of ordinary shares or ADS of the Company) held by the Trustee	​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Cost ​ treasury shares (in US$’000) As at December 31, 2019 ​ 941,310 ​ 6,079 Purchased ​ 3,281,920 ​ 12,904 Vested ​ (712,555) ​ (4,828) As at December 31, 2020 ​ 3,510,675 ​ 14,155 Purchased ​ 4,821,680 ​ 26,758 Vested ​ (271,595) ​ (1,416) As at June 30, 2021 ​ 8,060,760 ​ 39,497 ​
Schedule of share-based compensation expenses	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Research and development expenses 6,725 3,145 Selling and administrative expenses 3,542 756 Cost of revenues ​ 165 ​ 60 ​ ​ 10,432 ​ 3,961 Recorded with a corresponding credit to: ​ ​ ​ ​ Liability ​ 5,814 ​ 2,840 Additional paid-in capital ​ 4,618 ​ 1,121 ​ 10,432 3,961 ​

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of disaggregated revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Oncology/ ​ ​ ​ ​ Immunology ​ Other Ventures ​ Total ​ ​ (in US$’000) Goods—Marketed Products 16,948 — 16,948 —Distribution — 114,511 114,511 Services—Commercialization—Marketed Products 15,030 — 15,030 —Collaboration Research and Development ​ 4,795 ​ — ​ 4,795 —Research and Development ​ 261 ​ — ​ 261 Royalties ​ 5,817 ​ — ​ 5,817 ​ 42,851 114,511 157,362 ​ Third parties 42,590 112,200 154,790 Related parties (Note 16(i)) 261 2,311 2,572 ​ ​ 42,851 ​ 114,511 ​ 157,362 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ Oncology/ ​ ​ ​ Immunology ​ Other Ventures ​ Total ​ ​ (in US$’000) Goods—Marketed Products 6,600 — 6,600 —Distribution ​ — ​ 90,373 ​ 90,373 Services—Collaboration Research and Development 7,507 — 7,507 —Research and Development ​ 240 ​ — ​ 240 Royalties 2,045 — 2,045 ​ ​ 16,392 ​ 90,373 ​ 106,765 ​ ​ ​ ​ ​ ​ ​ Third parties 16,152 88,289 104,441 Related parties (Note 16(i)) 240 2,084 2,324 ​ ​ 16,392 ​ 90,373 ​ 106,765

Research and Development Expe_2

Research and Development Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Summary of research and development expenses	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Clinical trial related costs ​ 72,721 ​ 40,986 Personnel compensation and related costs ​ 41,056 ​ 29,356 Other research and development expenses ​ 9,273 ​ 3,632 ​ ​ 123,050 ​ 73,974

Significant Transactions with_2

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of transactions with related parties	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Sales to: ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison Holdings Limited (“CK Hutchison”) ​ 2,311 ​ 2,084 Revenue from research and development services from: ​ ​ ​ ​ An equity investee ​ 261 ​ 240 Purchases from: ​ ​ ​ ​ Equity investees ​ 1,954 ​ 1,887 Rendering of marketing services from: ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison ​ 186 ​ 152 Rendering of management services from: ​ ​ ​ ​ An indirect subsidiary of CK Hutchison ​ 485 ​ 478
Schedule of balances with related parties	​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 ​ (in US$’000) Accounts receivable—related parties ​ ​ ​ ​ Indirect subsidiaries of CK Hutchison (note (a)) ​ 664 ​ 1,222 An equity investee (note (a)) ​ 261 ​ — ​ ​ 925 ​ 1,222 Amounts due from related parties ​ ​ ​ ​ Equity investees (note (a) and (b)) ​ 24,225 ​ 1,142 Amounts due to a related party ​ ​ ​ ​ An indirect subsidiary of CK Hutchison (note (c)) ​ 428 ​ 401 Other deferred income ​ ​ ​ ​ An equity investee (note (d)) ​ 841 ​ 950 ​ Notes: (a) Balances with related parties are unsecured, repayable on demand and interest-free. The carrying values of balances with related parties approximate their fair values due to their short-term maturities. (b) As at June 30, 2021 and December 31, 2020, the Group had dividend receivables from an equity investee of US$ 23,077,000 and nil respectively. (c) Amounts due to an indirect subsidiary of CK Hutchison are unsecured, repayable on demand and interest-bearing if not settled within one month . (d) Other d eferred income represents amount s recognized from granting of promotion and marketing rights .
Schedule of transactions with non-controlling shareholders of subsidiaries	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Sales 20,144 16,784 Purchases 7,211 6,625 Dividend paid 9,256 1,231
Schedule of balances with non-controlling shareholders of subsidiaries	​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 ​ ​ (in US$’000) Accounts receivable 9,051 6,184 Accounts payable 5,835 4,856 Other non-current liabilities Loan — 579

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of components of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Current tax ​ ​ ​ ​ HK ​ 226 ​ 232 PRC ​ 2,184 ​ 48 U.S. and others ​ 231 ​ 530 Total current tax ​ 2,641 ​ 810 Deferred income tax ​ (782) ​ 1,222 Income tax expense ​ 1,859 ​ 2,032 ​
Schedule of reconciliation of the Group's reported income tax expense to the theoretical tax amount	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Loss before income taxes and equity in earnings of equity investees ​ (140,447) ​ (76,580) Tax calculated at the statutory tax rate of the Company ​ (23,174) ​ (12,636) Tax effects of: ​ ​ ​ ​ Different tax rates applicable in different jurisdictions ​ 3,585 ​ 1,431 Tax valuation allowance ​ 28,634 ​ 16,178 Preferential tax rate difference ​ (253) ​ (119) Preferential tax deduction and credits ​ (11,288) ​ (4,678) Expenses not deductible for tax purposes ​ 3,034 ​ 1,618 Utilization of previously unrecognized tax losses ​ (864) ​ (152) Withholding tax on undistributed earnings of PRC entities ​ 2,360 ​ 1,513 Income not subject to tax ​ (436) ​ (552) Others ​ 261 ​ (571) Income tax expense ​ 1,859 ​ 2,032

Losses Per Share (Tables)

Losses Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of basic losses per share	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 Weighted average number of outstanding ordinary shares in issue 729,239,181 685,285,841 Net loss attributable to the Company (US$’000) (102,397) (49,694) Losses per share attributable to the Company (US$ per share) (0.14) (0.07) ​

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of segment information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Revenue from external customers ​ 5,056 ​ — ​ 5,056 ​ 37,795 ​ 42,851 ​ 114,511 ​ — ​ 157,362 Interest income ​ 523 ​ 2 ​ 525 ​ — ​ 525 ​ 145 ​ 361 ​ 1,031 Equity in earnings of equity investees, net of tax ​ 40 ​ — ​ 40 ​ — ​ 40 ​ 42,926 ​ — ​ 42,966 Segment operating (loss)/profit ​ (69,961) ​ (62,341) ​ (132,302) ​ 4,707 ​ (127,595) ​ 44,663 ​ (14,307) ​ (97,239) Interest expense ​ — ​ — ​ — ​ — ​ — ​ — ​ 242 ​ 242 Income tax expense/(credit) ​ 109 ​ (1,492) ​ (1,383) ​ 571 ​ (812) ​ 265 ​ 2,406 ​ 1,859 Net (loss)/income attributable to the Company ​ (69,911) ​ (60,699) ​ (130,610) ​ 3,650 ​ (126,960) ​ 41,263 ​ (16,700) ​ (102,397) Depreciation/amortization ​ 3,198 ​ 67 ​ 3,265 ​ — ​ 3,265 ​ 160 ​ 97 ​ 3,522 Additions to non-current assets (other than financial instruments and deferred tax assets) ​ 10,183 ​ 466 ​ 10,649 ​ — ​ 10,649 ​ 632 ​ 66 ​ 11,347 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Total assets ​ 143,099 ​ 7,751 ​ 150,850 ​ 24,942 ​ 175,792 ​ 215,563 ​ 881,534 ​ 1,272,889 Property, plant and equipment ​ 27,160 ​ 853 ​ 28,013 ​ — ​ 28,013 ​ 713 ​ 442 ​ 29,168 Right-of-use assets ​ 4,455 ​ 1,284 ​ 5,739 ​ — ​ 5,739 ​ 2,686 ​ 1,098 ​ 9,523 Leasehold land ​ 13,092 ​ — ​ 13,092 ​ — ​ 13,092 ​ — ​ — ​ 13,092 Goodwill ​ — ​ — ​ — ​ — ​ — ​ 3,332 ​ — ​ 3,332 Other intangible asset ​ — ​ — ​ — ​ — ​ — ​ 194 ​ — ​ 194 Investments in equity investees ​ 426 ​ — ​ 426 ​ — ​ 426 ​ 117,890 ​ — ​ 118,316 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Revenue from external customers ​ 7,747 ​ — ​ 7,747 ​ 8,645 ​ 16,392 ​ 90,373 ​ — ​ 106,765 Interest income ​ 114 ​ — ​ 114 ​ — ​ 114 ​ 71 ​ 1,732 ​ 1,917 Equity in earnings of equity investees, net of tax ​ 68 ​ — ​ 68 ​ — ​ 68 ​ 30,298 ​ — ​ 30,366 Segment operating (loss)/profit ​ (53,454) ​ (19,923) ​ (73,377) ​ 5,048 ​ (68,329) ​ 32,300 ​ (9,674) ​ (45,703) Interest expense ​ — ​ — ​ — ​ — ​ — ​ — ​ 511 ​ 511 Income tax expense ​ 167 ​ 145 ​ 312 ​ — ​ 312 ​ 156 ​ 1,564 ​ 2,032 Net (loss)/income attributable to the Company ​ (53,590) ​ (20,018) ​ (73,608) ​ 5,035 ​ (68,573) ​ 30,438 ​ (11,559) ​ (49,694) Depreciation/amortization ​ 2,629 ​ 58 ​ 2,687 ​ — ​ 2,687 ​ 141 ​ 95 ​ 2,923 Additions to non-current assets (other than financial instruments and deferred tax assets) ​ 4,241 ​ 21 ​ 4,262 ​ — ​ 4,262 ​ 140 ​ 13 ​ 4,415 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ Oncology/Immunology ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketed ​ ​ ​ Other ​ ​ ​ ​ ​ R&D ​ Products ​ ​ ​ Ventures ​ ​ ​ ​ ​ ​ U.S. and ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC Others Subtotal PRC Subtotal PRC Unallocated Total ​ (in US$’000) Total assets ​ 127,637 ​ 9,957 ​ 137,594 ​ 5,728 ​ 143,322 ​ 231,234 ​ 349,562 ​ 724,118 Property, plant and equipment ​ 22,554 ​ 454 ​ 23,008 ​ — ​ 23,008 ​ 688 ​ 474 ​ 24,170 Right-of-use assets ​ 2,782 ​ 1,375 ​ 4,157 ​ — ​ 4,157 ​ 2,582 ​ 1,277 ​ 8,016 Leasehold land ​ 13,121 ​ — ​ 13,121 ​ — ​ 13,121 ​ — ​ — ​ 13,121 Goodwill ​ — ​ — ​ — ​ — ​ — ​ 3,307 ​ — ​ 3,307 Other intangible asset ​ — ​ — ​ — ​ — ​ — ​ 227 ​ — ​ 227 Investments in equity investees ​ 385 ​ — ​ 385 ​ — ​ 385 ​ 139,120 ​ — ​ 139,505 ​
Schedule of reconciliation of segment operating loss to net loss	​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ (in US$’000) Segment operating loss ​ (97,239) ​ (45,703) Interest expense ​ (242) ​ (511) Income tax expense ​ (1,859) ​ (2,032) Net loss ​ (99,340) ​ (48,246)

Note to Condensed Consolidate_2

Note to Condensed Consolidated Statements of Cash Flows (Tables)	6 Months Ended
	Jun. 30, 2021
Schedule of reconciliation of net loss for the period to net cash used in operating activities	​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 ​ ​ (in US$’000) Net loss ​ (99,340) ​ (48,246) Adjustments to reconcile net loss to net cash used in operating activities ​ ​ ​ ​ Depreciation and amortization ​ 3,522 ​ 2,923 Share-based compensation expense—share options ​ 7,925 ​ 3,006 Share-based compensation expense—LTIP ​ 10,432 ​ 3,961 Equity in earnings of equity investees, net of tax ​ (42,966) ​ (30,366) Dividends received from equity investees ​ 42,051 ​ 35,321 Changes in right-of-use assets ​ (1,468) ​ 205 Other adjustments ​ (2,464) ​ (740) Changes in working capital ​ ​ ​ ​ Accounts receivable—third parties ​ (11,234) ​ (3,205) Inventories ​ (5,669) ​ 1,171 Accounts payable ​ (3,099) ​ 1,910 Other payables, accruals and advance receipts ​ 33,836 ​ 7,313 Lease liabilities ​ 902 ​ (334) Other changes in working capital ​ (3,747) ​ (1,295) Total changes in working capital ​ 10,989 ​ 5,560 Net cash used in operating activities ​ (71,319) ​ (28,376)

Organization and Nature of Bu_2

Organization and Nature of Business (Details)	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021HKD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020HKD ($)
Segment reporting
Accumulated losses	$ 517,996,000			$ 415,591,000
Cash and cash equivalents	587,441,000			235,630,000
Short-term investments	363,007,000			199,546,000
Unutilized bank borrowing facilities	69,359,000		$ 541,000,000	$ 69,359,000	$ 541,000,000
Dividends received from equity investees	$ 42,051,000	$ 35,321,000

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents
Cash at bank and on hand (note (a))	$ 113,922,000	$ 87,828,000
Bank deposits maturing in three months or less (note (a))	473,519,000	147,802,000
Cash and cash equivalents	$ 587,441,000	$ 235,630,000
Bank deposits maturing in three months or less | Weighted average
Cash and Cash Equivalents
Effective interest rate (in percentage)	0.73%	1.12%
U.S. dollar ("US$")
Cash and Cash Equivalents
Cash and cash equivalents	$ 440,309,000	$ 164,201,000
Renminbi ("RMB")
Cash and Cash Equivalents
Cash and cash equivalents	74,061,000	64,258,000
UK Pound Sterling ("")
Cash and Cash Equivalents
Cash and cash equivalents	124,000	954,000
Hong Kong dollar ("HK$")
Cash and Cash Equivalents
Cash and cash equivalents	72,909,000	5,907,000
Euro
Cash and Cash Equivalents
Cash and cash equivalents	$ 38,000	$ 310,000

Short-term Investments (Details

Short-term Investments (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Short term investments
Short-term investments	$ 363,007,000	$ 199,546,000
Bank deposits maturing over three months
Short term investments
Short-term investments	$ 363,007,000	$ 199,546,000
Bank deposits maturing over three months | Weighted average
Short term investments
Effective interest rate (in percentage)	0.26%	1.06%
Bank deposits maturing over three months | Minimum
Short term investments
Bank deposit maturity period (in days)	91 days	91 days
Bank deposits maturing over three months | Maximum
Short term investments
Bank deposit maturity period (in days)	180 days	180 days
U.S. dollar ("US$") | Bank deposits maturing over three months
Short term investments
Short-term investments	$ 358,776,000	$ 187,961,000
Renminbi ("RMB") | Bank deposits maturing over three months
Short term investments
Short-term investments	1,154,000	612,000
Hong Kong dollar ("HK$") | Bank deposits maturing over three months
Short term investments
Short-term investments	$ 3,077,000	$ 10,973,000

Accounts Receivable-Third Par_3

Accounts Receivable-Third Parties (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Account Receivable
Accounts receivable, gross	$ 57,978	$ 46,743
Allowance for credit losses	(25)	(95)
Accounts receivable, net	$ 57,953	$ 46,648

Accounts Receivable-Third Par_4

Accounts Receivable-Third Parties - Movements on the allowance for credit losses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Allowance for Doubtful Accounts Receivable
As at January 1	$ 95	$ 16
Increase in allowance for credit losses	21	8
Decrease in allowance due to subsequent collection	(92)	(16)
Exchange difference	1
As at June 30	$ 25	$ 8

Accounts Receivable-Third Par_5

Accounts Receivable-Third Parties - aging analysis based on the relevant invoice dates (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 57,978	$ 46,743
Not later than 3 months
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	53,601	42,434
Between 3 months to 6 months
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	3,191	3,118
Between 6 months to 1 year
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	6	23
Later than 1 year
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,180	$ 1,168

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 8,202	$ 4,502
Finished goods	17,303	15,264
Total	$ 25,505	$ 19,766

Investments in Equity Investe_3

Investments in Equity Investees (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Investments in Equity Investees
Investments in equity investees		$ 118,316	$ 139,505
Deposit collected upon the signing of the SPA		15,912
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Investments in Equity Investees
Investments in equity investees		51,425	59,712
Cash consideration	$ 159,100
Deposit collected upon the signing of the SPA	15,900
Distributions of prior year undistributed profits and land bonus payment	52,300
Aggregate amount	211,400
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") | The Company
Investments in Equity Investees
Aggregate amount	$ 169,100
Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Investments in Equity Investees
Investments in equity investees		66,465	79,408
Other
Investments in Equity Investees
Investments in equity investees		$ 426	$ 385

Investments in Equity Investe_4

Investments in Equity Investees - Summarized Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Summarized balance sheet
Current assets	$ 1,091,174	$ 530,740
Current liabilities	(247,715)	(158,397)
Total shareholders' equity	1,013,695	518,949	$ 367,048	$ 312,903
Non-controlling interests	(28,900)	(34,833)
Net assets, excluding non-controlling interests	984,795	484,116
Equity Investees | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Summarized balance sheet
Current assets	194,035	177,888
Non-current assets	93,361	95,731
Current liabilities	(154,871)	(137,179)
Non-current liabilities	(28,673)	(16,034)
Total shareholders' equity	103,852	120,406
Non-controlling interests	(1,002)	(982)
Net assets, excluding non-controlling interests	102,850	119,424	56,330	44,541
Equity Investees | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Summarized balance sheet
Current assets	161,508	175,965
Non-current assets	93,211	93,361
Current liabilities	(119,821)	(109,873)
Non-current liabilities	(8,123)	(6,739)
Total shareholders' equity	126,775	152,714
Net assets, excluding non-controlling interests	$ 126,775	$ 152,714	$ 150,937	$ 146,759

Investments in Equity Investe_5

Investments in Equity Investees - Summarized Statements of Operations (Details) ¥ in Millions	1 Months Ended				6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021CNY (¥)	Nov. 30, 2020USD ($)	Nov. 30, 2020CNY (¥)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Summarized Statements of Operations
Total revenues					$ 157,362,000	$ 106,765,000
Interest income					1,031,000	1,917,000
Profit before taxation					(140,447,000)	(76,580,000)
Income tax expense					(1,859,000)	(2,032,000)
Net income					(99,340,000)	(48,246,000)
Non-controlling interests					(3,057,000)	(1,448,000)
Net income attributable to the shareholders of equity investee					(102,397,000)	(49,694,000)
Net (loss)/income					$ (99,340,000)	(48,246,000)
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Summarized Statements of Operations
Aggregated cash consideration	$ 103,100,000	¥ 679.5
Land compensation recognized			$ 86,100,000	¥ 569.2
Additional land compensation bonus	17,000,000	110.3
Gain before tax	16,600,000	107.6
Costs	$ 400,000	¥ 2.7
Preferential income tax rate (as a percent)					15.00%
Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Summarized Statements of Operations
Preferential income tax rate (as a percent)					15.00%
Other
Summarized Statements of Operations
Net income					$ 79,000	135,000
Net (loss)/income					79,000	135,000
Equity Investees | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Summarized Statements of Operations
Total revenues					153,689,000	124,098,000
Gross profit					82,251,000	60,794,000
Interest income					66,000	81,000
Finance cost						(5,000)
Profit before taxation					33,397,000	14,792,000
Income tax expense					(4,807,000)	(2,386,000)
Net income					28,590,000	12,406,000
Non-controlling interests					(14,000)	207,000
Net income attributable to the shareholders of equity investee					28,576,000	12,613,000
Net (loss)/income					28,590,000	12,406,000
Equity Investees | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Summarized Statements of Operations
Total revenues					180,413,000	150,703,000
Gross profit					138,979,000	112,363,000
Interest income					751,000	396,000
Profit before taxation					67,108,000	55,470,000
Income tax expense					(9,764,000)	(7,485,000)
Net income					57,344,000	47,985,000
Net income attributable to the shareholders of equity investee					57,344,000	47,985,000
Net (loss)/income					$ 57,344,000	$ 47,985,000

Investments in Equity Investe_6

Investments in Equity Investees - Reconciliation of Summarized Financial Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Opening net assets after non-controlling interests	$ 484,116
Net (loss)/income attributable to the Company	(102,397)	$ (49,694)
Purchase of additional interests in a subsidiary of an equity investee		$ (174)
Closing net assets after non-controlling interests	984,795
Carrying amount of investments	118,316		$ 139,505
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Additional interest acquired (as percent)		30.00%
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Carrying amount of investments	51,425		59,712
Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Carrying amount of investments	66,465		$ 79,408
Equity Investees | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Opening net assets after non-controlling interests	119,424	$ 44,541
Net (loss)/income attributable to the Company	28,576	12,613
Purchase of additional interests in a subsidiary of an equity investee		(347)
Dividends declared	(46,538)
Other comprehensive income/(loss)	1,388	(477)
Closing net assets after non-controlling interests	102,850	56,330
Group's share of net assets	51,425	28,165
Carrying amount of investments	51,425	28,165
Equity Investees | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees
Opening net assets after non-controlling interests	152,714	146,759
Net (loss)/income attributable to the Company	57,344	47,985
Dividends declared	(84,103)	(42,308)
Other comprehensive income/(loss)	820	(1,499)
Closing net assets after non-controlling interests	126,775	150,937
Group's share of net assets	63,387	75,468
Goodwill	3,078	2,821
Carrying amount of investments	$ 66,465	$ 78,289

Investments in Equity Investe_7

Investments in Equity Investees - Capital Commitments (Details) - Capital commitments $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Capital commitments
Property, plant and equipment - Contracted but not provided for	$ 44,793
Equity Investees
Capital commitments
Property, plant and equipment - Contracted but not provided for	$ 2,654

Accounts Payable (Details)

Accounts Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts payable	$ 28,513	$ 31,612

Accounts Payable - aging analys

Accounts Payable - aging analysis based on the relevant invoice dates (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts payable	$ 28,513	$ 31,612
Not later than 3 months
Accounts payable	22,935	26,270
Between 3 months to 6 months
Accounts payable	3,557	3,364
Between 6 months to 1 year
Accounts payable	813	782
Later than 1 year
Accounts payable	$ 1,208	$ 1,196

Other Payables, Accruals and _3

Other Payables, Accruals and Advance Receipts (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Payables, Accruals and Advance Receipts
Accrued salaries and benefits	$ 28,527	$ 21,982
Accrued research and development expenses	86,477	72,697
Accrued selling and marketing expenses	7,800	5,747
Accrued administrative and other general expenses	12,587	10,319
Accrued issuance costs	8,678	1,352
Deferred government grants	6,889	374
Deposits	1,636	1,408
Deposit received for divestment of HBYS (Note 7)	15,912
Others	13,104	7,003
Total other payables, accruals and advance receipts	$ 181,610	$ 120,882

Bank Borrowings - Schedule of B

Bank Borrowings - Schedule of Bank Borrowings (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Bank Borrowings
Current	$ 26,883
Non-current		$ 26,861
Bank borrowings	$ 26,883	$ 26,861
Weighted average interest rate for outstanding bank borrowings (as a percent)	1.10%	1.89%

Bank Borrowings - Loan Faciliti

Bank Borrowings - Loan Facilities (Details)	1 Months Ended
	Aug. 31, 2020HKD ($)	May 31, 2019HKD ($)	May 31, 2019USD ($)	Nov. 30, 2018HKD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Aug. 31, 2020USD ($)	May 31, 2019USD ($)	Nov. 30, 2018USD ($)
Unsecured credit facility
Bank Borrowings
Aggregate amount of credit facilities		$ 400,000,000						$ 51,282,000
Term (in years or months)		3 years	3 years
Unsecured credit facility | HIBOR
Bank Borrowings
Basis spread on variable rate (as a percent)		0.85%	0.85%
Revolving loan facility
Bank Borrowings
Aggregate amount of credit facilities	$ 117,000,000			$ 234,000,000			$ 15,000,000		$ 30,000,000
Term (in years or months)	2 years			3 years
Amount drawn from the credit facility					$ 0	$ 0
Revolving loan facility | HIBOR
Bank Borrowings
Basis spread on variable rate (as a percent)	4.50%
Revolving loan facility | Unsecured credit facility
Bank Borrowings
Aggregate amount of credit facilities		$ 190,000,000						24,359,000
Amount drawn from the credit facility					$ 0	$ 0
Revolving loan facility | Unsecured credit facility | HIBOR
Bank Borrowings
Basis spread on variable rate (as a percent)				0.85%
Term loan | Unsecured credit facility
Bank Borrowings
Aggregate amount of credit facilities		210,000,000						$ 26,923,000
Amount of upfront fee		$ 819,000	$ 105,000

Bank Borrowings - Schedule of M

Bank Borrowings - Schedule of Maturities of Bank Borrowings (Details)	Jun. 30, 2021USD ($)	Jun. 30, 2021HKD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020HKD ($)
Bank Borrowings
Not later than 1 year	$ 26,923,000
Between 1 to 2 years			$ 26,923,000
Bank borrowings	26,923,000		26,923,000
Unutilized bank borrowing facilities	$ 69,359,000	$ 541,000,000	$ 69,359,000	$ 541,000,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Capital commitments
Capital commitments
Property, plant and equipment - Contracted but not provided for	$ 44,793

Ordinary Shares (Details)

Ordinary Shares (Details) $ in Thousands	Jun. 30, 2021USD ($)Voteshares	Apr. 14, 2021USD ($)shares	Jun. 30, 2021USD ($)Voteshares	Jun. 30, 2020USD ($)	Dec. 31, 2020shares
Ordinary shares, authorized (in shares) | shares	1,500,000,000		1,500,000,000		1,500,000,000
Gross proceeds from issuance of shares			$ 634,909	$ 118,341
Issuance costs			$ 19,985	$ 7,863
Votes per ordinary share | Vote	1		1
Ordinary Shares
Number of ordinary shares issued | shares		16,393,445
Gross proceeds from issuance of shares		$ 100,000
Issuance costs		$ 100
Ordinary Shares | Public offering
Number of ordinary shares issued | shares	104,000,000
Gross proceeds from issuance of shares	$ 534,700
Issuance costs	$ 26,900

Share based Compensation - Hutc

Share based Compensation - Hutchmed Share Option Scheme (Details) - shares	Jun. 04, 2005	Jun. 30, 2021
Share option scheme expired in 2016
Share-based Compensation
Expiry period	10 years
Aggregate number of shares issuable		716,180
Hutchmed Share Option Scheme
Share-based Compensation
Aggregate number of shares issuable		50,613,268
Number of shares authorized but unissued		651,484,340
Hutchmed Share Option Scheme | Minimum
Share-based Compensation
Expiry period		8 years
Hutchmed Share Option Scheme | Maximum
Share-based Compensation
Expiry period		10 years
Hutchmed Share Option Scheme | Four-year awards
Share-based Compensation
Vesting period		4 years
Vesting percentage upon first anniversary		25.00%
Annual vesting percentage after the first anniversary		25.00%

Share-based Compensation - Hutc

Share-based Compensation - Hutchmed Share Option Activity (Details) - Hutchmed Share Option Scheme - GBP (£) £ / shares in Units, £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of share options
Outstanding as at beginning of period (in shares)	29,160,990	19,432,560
Granted (in shares)	8,279,900	15,437,080
Exercised (in shares)	(400,000)	(480,780)
Cancelled (in shares)	(817,800)	(4,486,200)
Expired (in shares)	(42,400)	(741,670)
Outstanding as at end of period (in shares)	36,180,690	29,160,990	19,432,560
Vested and exercisable (in shares)	15,374,075	11,529,280
Weighted average exercise price in GBP per share
Outstanding balance as at beginning of period (in GBP per share)	£ 3.40	£ 3.27
Granted (in GBP per share)	4.05	3.71
Exercised (in GBP per share)	0.44	0.96
Cancelled (in GBP per share)	4.31	3.85
Expired (in GBP per share)	4.33	4.62
Outstanding balance as at end of period (in GBP per share)	3.57	3.40	£ 3.27
Vested and exercisable (in GBP per share)	£ 3.11	£ 2.73
Weighted average remaining contractual life (years)
Outstanding (in years)	7 years 5 months 1 day	7 years 2 months 15 days	6 years 8 months 1 day
Vested and exercisable (in years)	5 years 3 months	4 years 6 months 25 days
Aggregate intrinsic value in GBP
Outstanding (in GBP)	£ 72,650	£ 35,654	£ 18,668
Vested and exercisable (in GBP)	£ 37,879	£ 21,864

Share-based Compensation - Hu_2

Share-based Compensation - Hutchmed Options Fair value Assumptions (Details) - Hutchmed Share Option Scheme - £ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation
Weighted average grant date fair value of share options (in GBP per share)	£ 1.51	£ 1.40
Significant inputs into the valuation model (weighted average):
Exercise price (in GBP per share)	4.05	3.71
Share price at effective date of grant (in GBP per share)	£ 4.01	£ 3.71
Expected volatility (note (a))	40.80%	42.60%
Risk-free interest rate (note (b))	1.68%	0.59%
Contractual life of share options (in years)	10 years	10 years
Expected dividend yield (note (c))	0.00%	0.00%

Share-based Compensation - Hu_3

Share-based Compensation - Hutchmed Share Option Exercises (Details) - Hutchmed Share Option Scheme $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Share option values
Cash received from share option exercises	$ 242
Total intrinsic value of share option exercises	$ 2,012

Share-based Compensation - Hu_4

Share-based Compensation - Hutchmed Share Based Compensation Expense (Details) - Hutchmed Share Option Scheme - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation
Share-based compensation expense	$ 7,925,000	$ 3,006,000
Unrecognized compensation cost	$ 26,901,000
Unrecognized compensation cost - weighted-average remaining service period (in years)	3 years 3 months 18 days
Research and development expenses
Share-based Compensation
Share-based compensation expense	$ 4,101,000	1,697,000
Selling and administrative expenses
Share-based Compensation
Share-based compensation expense	3,749,000	1,237,000
Cost of revenues
Share-based Compensation
Share-based compensation expense	$ 75,000	$ 72,000

Share-based Compensation - LTIP

Share-based Compensation - LTIP (Details) - LTIP - USD ($)	Mar. 26, 2021	Aug. 12, 2020	Apr. 20, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Shared-based Compensation Award, Performance
Share-based Compensation
Number of business days for vesting after announcement of Group's annual results	2 days	2 days	2 days
Number of years after the covered financial year to which the LTIP award relates	2 years	2 years	2 years
Vesting percentage on each of the first, second, third and fourth anniversaries		25.00%	25.00%
Shared-based Compensation Award, Performance | Grant Date, April 20, 2020, One
Share-based Compensation
Maximum cash amount per annum			$ 5,300,000
Shared-based Compensation Award, Performance | Grant Date, April 20, 2020, Two
Share-based Compensation
Maximum cash amount per annum			37,400,000
Shared-based Compensation Award, Performance | Grant Date, April 20, 2020, Three
Share-based Compensation
Maximum cash amount per annum			1,900,000
Shared-based Compensation Award, Performance | Grant Date, April 20, 2020, Four
Share-based Compensation
Maximum cash amount per annum			$ 200,000
Shared-based Compensation Award, Performance | Grant Date, August 12, 2020, One
Share-based Compensation
Maximum cash amount per annum		$ 2,100,000
Shared-based Compensation Award, Performance | Grant Date, August 12, 2020, Two
Share-based Compensation
Maximum cash amount per annum		$ 300,000
Shared-based Compensation Award, Performance | Grant Date, March 26 2021
Share-based Compensation
Maximum cash amount per annum	$ 57,300,000
Shared-based Compensation Award, Non-performance
Share-based Compensation
Number of business days for vesting after announcement of Group's annual results			2 days
Number of years after the covered financial year to which the LTIP award relates			2 years
Awarded Shares
Ordinary Shares Held by Trustee - Number of treasury shares
As at beginning of period				3,510,675	941,310	941,310
Purchased				4,821,680		3,281,920
Vested				(271,595)		(712,555)
As at end of period				8,060,760		3,510,675
Ordinary Shares Held by Trustee - Cost
As at beginning of period				$ 14,155,000	$ 6,079,000	$ 6,079,000
Purchased				26,758,000		12,904,000
Vested				(1,416,000)		(4,828,000)
As at end of period				39,497,000		$ 14,155,000
Awards forfeited				$ 2,532,000	$ 430,000

Share-based Compensation - LT_2

Share-based Compensation - LTIP Share Based Compensation Expense (Details) - LTIP - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share-based Compensation
Share-based compensation expense	$ 10,432,000	$ 3,961,000
Share-based compensation reclassified from liability to additional paid-in capital	8,516,000	4,092,000
Share-based compensation recorded as liability	4,387,000		$ 7,089,000
Unrecognized compensation cost	65,893,000
Liability
Share-based Compensation
Share-based compensation expense	5,814,000	2,840,000
Additional Paid-in Capital
Share-based Compensation
Share-based compensation expense	4,618,000	1,121,000
Research and development expenses
Share-based Compensation
Share-based compensation expense	6,725,000	3,145,000
Selling and administrative expenses
Share-based Compensation
Share-based compensation expense	3,542,000	756,000
Cost of revenues
Share-based Compensation
Share-based compensation expense	$ 165,000	$ 60,000

Revenues (Details)

Revenues (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues
Total revenues	$ 157,362	$ 106,765
Third parties
Revenues
Total revenues	154,790	104,441
Related parties
Revenues
Total revenues	2,572	2,324
Goods-Marketed Products
Revenues
Total revenues	16,948	6,600
Goods-Distribution
Revenues
Total revenues	114,511	90,373
Commercialization services
Revenues
Total revenues	15,030
Commercialization services | Third parties
Revenues
Total revenues	15,030
Collaboration research and development services
Revenues
Total revenues	4,795	7,507
Collaboration research and development services | Third parties
Revenues
Total revenues	4,795	7,507
Research and development services
Revenues
Total revenues	261	240
Research and development services | Related parties
Revenues
Total revenues	261	240
Royalties
Revenues
Total revenues	5,817	2,045
Royalties | Third parties
Revenues
Total revenues	5,817	2,045
Oncology/Immunology segment
Revenues
Total revenues	42,851	16,392
Oncology/Immunology segment | Third parties
Revenues
Total revenues	42,590	16,152
Oncology/Immunology segment | Related parties
Revenues
Total revenues	261	240
Oncology/Immunology segment | Goods-Marketed Products
Revenues
Total revenues	16,948	6,600
Oncology/Immunology segment | Commercialization services
Revenues
Total revenues	15,030
Oncology/Immunology segment | Collaboration research and development services
Revenues
Total revenues	4,795	7,507
Oncology/Immunology segment | Research and development services
Revenues
Total revenues	261	240
Oncology/Immunology segment | Royalties
Revenues
Total revenues	5,817	2,045
Other Ventures segment
Revenues
Total revenues	114,511	90,373
Other Ventures segment | Third parties
Revenues
Total revenues	112,200	88,289
Other Ventures segment | Related parties
Revenues
Total revenues	2,311	2,084
Other Ventures segment | Goods-Distribution
Revenues
Total revenues	$ 114,511	$ 90,373

Research and Development Expe_3

Research and Development Expenses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Clinical trial related costs	$ 72,721	$ 40,986
Personnel compensation and related costs	41,056	29,356
Other research and development expenses	9,273	3,632
Research and development expenses	$ 123,050	$ 73,974

Research and Development Expe_4

Research and Development Expenses - Additional information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	$ 123,050,000	$ 73,974,000
Collaborative arrangements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	$ 6,146,000	$ 2,360,000

Significant Transactions with_3

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Related parties (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Balances with related parties included in:
Accounts receivable-related parties	$ 925,000		$ 1,222,000
Amounts due from related parties	24,225,000		1,142,000
Indirect subsidiaries of CK Hutchison
Balances with related parties included in:
Accounts receivable-related parties	664,000		1,222,000
Amounts due to a related party	$ 428,000		$ 401,000
Period of repayable on demand and interest-bearing (in months)	1 month		1 month
Equity investees
Related party transaction
Purchases	$ 1,954,000	$ 1,887,000
Balances with related parties included in:
Accounts receivable-related parties	261,000
Amounts due from related parties	24,225,000		$ 1,142,000
Other deferred income	841,000		950,000
Sales | Indirect subsidiaries of CK Hutchison
Related party transaction
Sales	2,311,000	2,084,000
Research and development services | Equity investees
Related party transaction
Sales	261,000	240,000
Marketing services | Indirect subsidiaries of CK Hutchison
Related party transaction
Expenses	186,000	152,000
Management services | Indirect subsidiaries of CK Hutchison
Related party transaction
Expenses	485,000	$ 478,000
Dividend receivable | Equity investees
Balances with related parties included in:
Dividend receivables	$ 23,077,000		$ 0

Significant Transactions with_4

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Non-controlling shareholders of subsidiaries (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Transactions with non-controlling shareholders of subsidiaries:
Sales	$ 157,362	$ 106,765
Balances with non-controlling shareholders of subsidiaries included in:
Accounts receivable	57,953		$ 46,648
Accounts payable	28,513		31,612
Other non-current liabilities	5,522		13,847
Non-controlling shareholders of subsidiaries
Transactions with non-controlling shareholders of subsidiaries:
Sales	20,144	16,784
Purchases	7,211	6,625
Dividend paid	9,256	$ 1,231
Balances with non-controlling shareholders of subsidiaries included in:
Accounts receivable	9,051		6,184
Accounts payable	$ 5,835		4,856
Non-controlling shareholders of subsidiaries | Loan
Balances with non-controlling shareholders of subsidiaries included in:
Other non-current liabilities			$ 579

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Current tax	$ 2,641	$ 810
Deferred income tax	(782)	1,222
Income tax expense	1,859	2,032
Reconciliation of reported income tax expense to the theoretical tax amount
Loss before income taxes and equity in earnings of equity investees	(140,447)	(76,580)
Tax calculated at the statutory tax rate of the Company	(23,174)	(12,636)
Tax effects of:
Different tax rates applicable in different jurisdictions	3,585	1,431
Tax valuation allowance	28,634	16,178
Preferential tax rate difference	(253)	(119)
Preferential tax deduction and credits	(11,288)	(4,678)
Expenses not deductible for tax purposes	3,034	1,618
Utilization of previously unrecognized tax losses	(864)	(152)
Withholding tax on undistributed earnings of PRC entities	2,360	1,513
Income not subject to tax	(436)	(552)
Others	261	(571)
Income tax expense	1,859	2,032
Hong Kong
Current tax	226	232
PRC
Current tax	2,184	48
U.S. and others
Current tax	$ 231	$ 530

Losses Per Share (Details)

Losses Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Basic losses per share
Weighted average number of outstanding ordinary shares in issue	729,239,181	685,285,841
Net loss attributable to the Company (US$'000)	$ (102,397)	$ (49,694)
Losses per share attributable to the Company (US$ per share)	$ (0.14)	$ (0.07)

Segment Reporting (Details)

Segment Reporting (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)area	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of core business areas | area	2
Revenue from external customers	$ 157,362	$ 106,765
Interest income	1,031	1,917
Equity in earnings of equity investees, net of tax	42,966	30,366
Segment operating (loss)/profit	(97,239)	(45,703)
Interest expense	242	511
Income tax expense/(credit)	1,859	2,032
Net (loss)/income attributable to the Company	(102,397)	(49,694)
Depreciation/amortization	3,522	2,923
Additions to non-current assets (other than financial instruments and deferred tax assets)	11,347	4,415
Segment Reporting Information, Additional Information [Abstract]
Total assets	1,272,889		$ 724,118
Property, plant and equipment	29,168		24,170
Right-of-use assets	9,523		8,016
Leasehold land	13,092		13,121
Goodwill	3,332		3,307
Other intangible asset	194		227
Investments in equity investees	118,316		139,505
Oncology/Immunology segment
Segment Reporting Information [Line Items]
Revenue from external customers	42,851	16,392
Other Ventures segment
Segment Reporting Information [Line Items]
Revenue from external customers	114,511	90,373
Reportable segment | Oncology/Immunology segment
Segment Reporting Information [Line Items]
Revenue from external customers	42,851	16,392
Interest income	525	114
Equity in earnings of equity investees, net of tax	40	68
Segment operating (loss)/profit	(127,595)	(68,329)
Income tax expense/(credit)	(812)	312
Net (loss)/income attributable to the Company	(126,960)	(68,573)
Depreciation/amortization	3,265	2,687
Additions to non-current assets (other than financial instruments and deferred tax assets)	10,649	4,262
Segment Reporting Information, Additional Information [Abstract]
Total assets	175,792		143,322
Property, plant and equipment	28,013		23,008
Right-of-use assets	5,739		4,157
Leasehold land	13,092		13,121
Investments in equity investees	426		385
Reportable segment | Oncology/Immunology segment | R&D
Segment Reporting Information [Line Items]
Revenue from external customers	5,056	7,747
Interest income	525	114
Equity in earnings of equity investees, net of tax	40	68
Segment operating (loss)/profit	(132,302)	(73,377)
Income tax expense/(credit)	(1,383)	312
Net (loss)/income attributable to the Company	(130,610)	(73,608)
Depreciation/amortization	3,265	2,687
Additions to non-current assets (other than financial instruments and deferred tax assets)	10,649	4,262
Segment Reporting Information, Additional Information [Abstract]
Total assets	150,850		137,594
Property, plant and equipment	28,013		23,008
Right-of-use assets	5,739		4,157
Leasehold land	13,092		13,121
Investments in equity investees	426		385
Reportable segment | Oncology/Immunology segment | R&D | PRC
Segment Reporting Information [Line Items]
Revenue from external customers	5,056	7,747
Interest income	523	114
Equity in earnings of equity investees, net of tax	40	68
Segment operating (loss)/profit	(69,961)	(53,454)
Income tax expense/(credit)	109	167
Net (loss)/income attributable to the Company	(69,911)	(53,590)
Depreciation/amortization	3,198	2,629
Additions to non-current assets (other than financial instruments and deferred tax assets)	10,183	4,241
Segment Reporting Information, Additional Information [Abstract]
Total assets	143,099		127,637
Property, plant and equipment	27,160		22,554
Right-of-use assets	4,455		2,782
Leasehold land	13,092		13,121
Investments in equity investees	426		385
Reportable segment | Oncology/Immunology segment | R&D | U.S. and others
Segment Reporting Information [Line Items]
Interest income	2
Segment operating (loss)/profit	(62,341)	(19,923)
Income tax expense/(credit)	(1,492)	145
Net (loss)/income attributable to the Company	(60,699)	(20,018)
Depreciation/amortization	67	58
Additions to non-current assets (other than financial instruments and deferred tax assets)	466	21
Segment Reporting Information, Additional Information [Abstract]
Total assets	7,751		9,957
Property, plant and equipment	853		454
Right-of-use assets	1,284		1,375
Reportable segment | Oncology/Immunology segment | Marketed Products | PRC
Segment Reporting Information [Line Items]
Revenue from external customers	37,795	8,645
Segment operating (loss)/profit	4,707	5,048
Income tax expense/(credit)	571
Net (loss)/income attributable to the Company	3,650	5,035
Segment Reporting Information, Additional Information [Abstract]
Total assets	24,942		5,728
Reportable segment | Other Ventures segment | PRC
Segment Reporting Information [Line Items]
Revenue from external customers	114,511	90,373
Interest income	145	71
Equity in earnings of equity investees, net of tax	42,926	30,298
Segment operating (loss)/profit	44,663	32,300
Income tax expense/(credit)	265	156
Net (loss)/income attributable to the Company	41,263	30,438
Depreciation/amortization	160	141
Additions to non-current assets (other than financial instruments and deferred tax assets)	632	140
Segment Reporting Information, Additional Information [Abstract]
Total assets	215,563		231,234
Property, plant and equipment	713		688
Right-of-use assets	2,686		2,582
Goodwill	3,332		3,307
Other intangible asset	194		227
Investments in equity investees	117,890		139,120
Unallocated
Segment Reporting Information [Line Items]
Interest income	361	1,732
Segment operating (loss)/profit	(14,307)	(9,674)
Interest expense	242	511
Income tax expense/(credit)	2,406	1,564
Net (loss)/income attributable to the Company	(16,700)	(11,559)
Depreciation/amortization	97	95
Additions to non-current assets (other than financial instruments and deferred tax assets)	66	$ 13
Segment Reporting Information, Additional Information [Abstract]
Total assets	881,534		349,562
Property, plant and equipment	442		474
Right-of-use assets	$ 1,098		$ 1,277

Segment Reporting - Elimination

Segment Reporting - Elimination (Details)	6 Months Ended
	Jun. 30, 2021USD ($)customer	Jun. 30, 2020USD ($)customer
Revenue from External Customers
Revenue from external customers	$ 157,362,000	$ 106,765,000
Oncology/Immunology segment
Revenue from External Customers
Revenue from external customers	42,851,000	16,392,000
Oncology/Immunology segment | Customer | Revenue | One customer
Revenue from External Customers
Revenue from external customers	$ 30,981,000	$ 10,846,000
Number of customers accounted for more than 10% of revenue | customer	1	1
Other Ventures segment
Revenue from External Customers
Revenue from external customers	$ 114,511,000	$ 90,373,000
Other Ventures segment | Customer | Revenue | One customer
Revenue from External Customers
Revenue from external customers	$ 20,144,000	$ 16,784,000
Number of customers accounted for more than 10% of revenue | customer	1	1
Intersegment elimination
Revenue from External Customers
Revenue from external customers	$ 14,837,000,000	$ 6,554,000,000

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of segment operating loss to net loss (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Segment reporting
Segment operating loss	$ (97,239)	$ (45,703)
Interest expense	(242)	(511)
Income tax expense	(1,859)	(2,032)
Net income	$ (99,340)	$ (48,246)

Note to Condensed Consolidate_3

Note to Condensed Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (99,340)	$ (48,246)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,522	2,923
Share-based compensation expense-share options	7,925	3,006
Share-based compensation expense-LTIP	10,432	3,961
Equity in earnings of equity investees, net of tax	(42,966)	(30,366)
Dividends received from equity investees	42,051	35,321
Changes in right-of-use assets	(1,468)	205
Other adjustments	(2,464)	(740)
Changes in working capital
Accounts receivable-third parties	(11,234)	(3,205)
Inventories	(5,669)	1,171
Accounts payable	(3,099)	1,910
Other payables, accruals and advance receipts	33,836	7,313
Lease liabilities	902	(334)
Other changes in working capital	(3,747)	(1,295)
Total changes in working capital	10,989	5,560
Net cash used in operating activities	$ (71,319)	$ (28,376)

Litigation (Details)

Litigation (Details) $ in Thousands	Jun. 30, 2021USD ($)claim	Dec. 31, 2020USD ($)
Number of claims or actions pending | claim	0
Accounts receivable	$ 57,953	$ 46,648
Accounts payable	28,513	31,612
Other payables	181,610	$ 120,882
Seroquel
Accounts receivable	1,200
Long-term prepayment	800
Accounts payable	1,000
Other payables	$ 1,300

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	Jul. 12, 2021USD ($)shares	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jul. 12, 2021$ / shares
Proceeds from issuance of ordinary shares		$ 634,909	$ 118,341
Subsequent Events | Over-allotment option
Number of ordinary shares issued | shares	15,600,000
Share price | $ / shares				$ 40.10
Proceeds from issuance of ordinary shares	$ 80,200